Process for the preparation of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Abstract

Provided herein are processes for the preparation of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, which are useful for treating, preventing, and managing a variety of disorders. Also provided are solid forms of various intermediates and products obtained from the processes. TIFF2024522748000054.tif38154

Description

[Technical field]

[0001] 1. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Patent Application No. 63 / 213,043, filed June 21, 2021, which is incorporated by reference in its entirety.

[0002] Provided herein are processes for the preparation of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, which are useful for treating, preventing, and managing a variety of disorders. [Background technology]

[0003] Cancer is primarily characterized by an increase in the number of abnormal cells originating from a given normal tissue, the invasion of adjacent tissues by these abnormal cells, or the lymphatic or blood-borne spread and metastasis of malignant cells to regional lymph nodes. Clinical data and molecular biology studies have shown that cancer is a multi-step process beginning with small pre-neoplastic changes that can progress to neoplasms under certain conditions. Neoplastic lesions can evolve clonally and develop increased capacities for invasion, proliferation, metastasis, and heterogeneity, especially under conditions where neoplastic cells evade the host's immune surveillance. In order to eradicate neoplastic cells in patients, current cancer treatments may include surgery, chemotherapy, hormonal therapy, and / or radiation treatments. Recent advances in cancer therapeutics are described by Dr. G. K., et al., Cancer Therapeutics, vol. 1, no. 1, pp. 1111-1115, 2002.

[0004] Hematological malignancies are cancers that begin in blood-forming tissues, such as bone marrow, or cells of the immune system. Examples of hematological malignancies are leukemia, lymphoma, and myeloma. More specific examples of hematological malignancies include, but are not limited to, acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL), T-cell lymphoma (TCL), Burkitt's lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone lymphoma (MZL), and myelodysplastic syndromes (MDS).

[0005] Certain 4-aminoisoindoline-1,3-dione compounds, including (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, have been reported to be effective against a variety of hematological cancer cell lines. See U.S. Patent Nos. 5,393,343 and 5,433,621, each of which is incorporated herein by reference in its entirety. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] US Patent Application Publication No. 2019 / 0322647 [Patent Document 2] US Patent Application Publication No. 2020 / 0325129 [Non-patent literature]

[0007] [Non-Patent Document 1] Rajkumar et al.in Nature Reviews Clinical Oncology 11,628-630(2014) Summary of the Invention [Problem to be solved by the invention]

[0008] Methods for the synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and its racemate have been previously described in U.S. Patent Application Publication No. 2019 / 0322647. There remains a need for efficient, scalable methods for preparing (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. [Means for solving the problem]

[0009] In one embodiment, the present specification provides a compound of formula (I): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologues thereof, comprising the steps of: (Step 1.0) Formula (II): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof to provide a compound of formula (I) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof; (Step 1.1) Optionally, converting a compound of formula (I) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof into a salt of the compound; A method is provided that includes:

[0010] In one embodiment, the present disclosure relates to Compound 1: [ka] A solid form (e.g., Form B) is provided that comprises a besylate salt of

[0011] In one embodiment, the present disclosure relates to compound 3: [ka] In one embodiment, a solid form (e.g., Form A or Form B) is provided that comprises the hydrochloride salt of

[0012] In one embodiment, the present disclosure relates to compound 4: [ka] A solid form (e.g., Form A) is provided that comprises the methanesulfonate salt of [Brief description of the drawings]

[0013] [Figure 1] 1 provides a representative XRPD pattern of Form B of the besylate salt of Compound 1. [Diagram 2] 1 provides a representative TGA thermogram of Form B of the besylate salt of Compound 1. [Diagram 3] 1 provides a representative DSC thermogram of Form B of the besylate salt of Compound 1. [Figure 4] 1 provides a representative XRPD pattern of Form A of the hydrochloride salt of Compound 1 produced according to the methods described herein (a) compared to a reference sample (b). [Diagram 5] 1 provides a representative XRPD pattern of Form A of the hydrochloride salt of Compound 3. [Figure 6] 1 provides a representative DSC thermogram of Form A of the hydrochloride salt of Compound 3. [Figure 7] 1 provides a representative XRPD pattern of Form B of the hydrochloride salt of Compound 3. [Figure 8] 1 provides a representative TGA thermogram of Form B of the hydrochloride salt of Compound 3. [Figure 9] 1 provides a representative DSC thermogram of Form B of the hydrochloride salt of Compound 3. [Figure 10] 1 provides a representative XRPD pattern of Form A of the methanesulfonate salt of compound 4. [Figure 11] 1 provides a representative DSC thermogram of Form A of the methanesulfonate salt of Compound 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] 6.1 Definition As used herein and unless otherwise stated, the term "method" provided herein refers to the method provided herein that is useful for preparing the compounds provided herein. Modifications of the methods provided herein (e.g., starting materials, reagents, protecting groups, solvents, temperatures, reaction times, purification) are also encompassed by the present disclosure. In general, the technical teachings of one embodiment provided herein can be combined with those disclosed in any other embodiment provided herein.

[0015] The use of the words "a" or "an," when used in conjunction with the term "comprising" in the claims and / or this specification, can mean "one," but is also consistent with the meaning of "one or more," "at least one," and "one or more."

[0016] As used herein, the terms "comprise" and "comprise" can be used interchangeably. The terms "comprise" and "comprise" should be interpreted to specify the presence of the mentioned described features or components, but do not exclude the presence or addition of one or more features or components or groups thereof. Furthermore, the terms "comprise" and "comprise" are intended to include examples encompassed by the term "consisting of". Thus, the term "consisting of" can be used in place of the terms "comprise" and "comprise" to provide more specific embodiments of the present invention.

[0017] The term "consisting of" means that the subject matter has at least 90%, 95%, 97%, 98% or 99% of the recited features or components that make it up. In another embodiment, the term "consisting of" excludes from the scope of any succeeding recitation any other features or components, excepting those that are not essential to the technical effect to be achieved.

[0018] As used herein, the term "or" should be interpreted as an inclusive "or" meaning any one or any combination. Thus, "A, B or C" means any of the following: "A; B; C; A and B; A and C; B and C; A, B and C." Exceptions to this definition may occur only if combinations of elements, features, steps or acts are in some way inherently mutually exclusive.

[0019] As used herein and unless otherwise stated, terms such as "adding," "reacting," or "treating" refer to contacting one reactant, reagent, solvent, catalyst, or reactive group, etc. with another reactant, reagent, solvent, catalyst, or reactive group, etc. The reactants, reagents, solvents, catalysts, or reactive groups, etc. can be added individually, simultaneously, or separately, and can be added in any order. The reactants, reagents, solvents, catalysts, or reactive groups, etc. can each be added at once (which can be delivered all at once or over a period of time) or separately (again, which can be delivered all at once or over a period of time). They can be added in the presence or absence of heat, and can optionally be added in an inert atmosphere. "Reacting" can refer to in situ formation or to an intramolecular reaction if the reactive groups are in the same molecule.

[0020] As used herein, and unless otherwise stated, the term "converting" refers to subjecting the compound at hand to suitable reaction conditions to effect the formation of the desired compound at hand.

[0021] As used herein and unless otherwise stated, the term "salt" includes, but is not limited to, salts of acidic or basic groups that may be present in the compounds provided herein. Compounds that are basic in nature can form various types of salts with various inorganic and organic acids. Acids that can be used to prepare salts of such basic compounds include acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, bromide, iodide, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolyl arsanilate, hexylresorcinate, hydrabamine, hydrochloride, ethyl methacrylate ... Those that form salts with anions, including but not limited to xinaphthoate, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylsulfate, muscat, napsylate, nitrate, pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, succinate, sulfate, tannate, tartrate, theoclate, triethiodide and pamoate. Compounds that contain amino groups can also form salts with various amino acids in addition to the acids mentioned above. Compounds that are acidic in nature can form base salts with various cations. Non-limiting examples of such salts include alkali metal or alkaline earth metal salts, in some embodiments calcium salts, magnesium salts, sodium salts, lithium salts, zinc salts, potassium salts and iron salts. Compounds that are acidic in nature can also form base salts with compounds that contain amino groups.

[0022] As used herein and unless otherwise specified, the term "solvate" means a compound that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. When the solvent is water, the solvate is a hydrate.

[0023] As used herein, and unless otherwise specified, the term "stereoisomer" includes all enantiomerically / stereomerically pure and enantiomerically / stereomerically enriched compounds provided herein.

[0024] When the stereochemistry of a structure or portion thereof is not shown (e.g., using bold or dashed lines), the structure or portion thereof should be interpreted as encompassing all enantiomerically pure compounds, enantiomerically enriched compounds, diastereomerically pure compounds, diastereomerically enriched compounds, and racemic mixtures of these compounds.

[0025] Unless otherwise stated, the terms "enantiomerically enriched" and "enantiomerically pure", as used interchangeably herein, refer to a composition in which the weight percentage of one enantiomer is greater than the amount of that one enantiomer in a control mixture of racemic composition (e.g., greater than 1:1 by weight). For example, an enantiomerically enriched preparation of the (S)-enantiomer refers to a preparation of a compound having more than 50% by weight, such as at least 75% by weight, or even at least 80% by weight, of the (S)-enantiomer relative to the (R)-enantiomer. In some embodiments, the enrichment can be much greater than 80% by weight, and "substantially optically enriched", "substantially enantiomerically enriched", "substantially enantiomerically pure" or "substantially non-racemic" preparations are provided, which refer to preparations of a composition having at least 85% by weight, such as at least 90% by weight, such as at least 95% by weight, of one enantiomer relative to the other enantiomer. In one embodiment, the composition has about 99% by weight of one enantiomer relative to the other enantiomer. In one embodiment, the composition has at least more than 99% by weight of one enantiomer relative to the other enantiomer. In some embodiments, the enantiomerically enriched composition has a higher potency in terms of therapeutic utility per unit mass than the racemic mixture of the composition.

[0026] As used herein and unless otherwise specified, the term "solid form" and related terms refer to a physical form that is not predominantly in a liquid or gaseous state. As used herein, the terms "solid form" (singular and plural) include semi-solids. Solid forms may be crystalline, amorphous, partially crystalline, partially amorphous, or a mixture of these forms.

[0027] The solid forms provided herein may have various degrees of crystallinity or lattice order. The solid forms provided herein are not limited by any particular degree of crystallinity or lattice order and may be 0-100% crystalline. Methods for determining crystallinity are known to those skilled in the art, for example, those described in Suryanarayanan, R., X-Ray Power Diffractometry, Physical Characterization of Pharmaceutical Salts, HGBrittain, Editor, Mercel Dekkter, Murray Hill, NJ, 1995, pp. 187-199, which is incorporated herein by reference in its entirety. In some embodiments, the solid forms provided herein are about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% crystalline.

[0028] As used herein, and unless otherwise specified, the term "crystalline" and related terms, when used to describe a substance, component, product, or form, means that the substance, component, product, or form is substantially crystalline, for example, as determined by X-ray diffraction. See, e.g., Remington: The Science and Practice of Pharmacy, 21 st edition, Lippincott, Williams and Wilkins, Baltimore, MD (2005); The United States Pharmacopeia, 23 rd Please refer to the above edition, 1843-1844 (1995).

[0029] As used herein and unless otherwise specified, the term "crystalline form" and related terms herein refer to a solid form that is crystalline. Crystalline forms include single-component and multi-component crystalline forms, and include, but are not limited to, polymorphs, solvates, hydrates, and other molecular complexes, as well as salts, solvates of salts, hydrates of salts, co-crystals of salts, other molecular complexes of salts, and polymorphs thereof. In certain embodiments, the crystalline form of a substance may be substantially free of amorphous forms and / or other crystalline forms. In certain embodiments, the crystalline form of a substance may contain less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% of one or more amorphous forms and / or other crystalline forms by weight. In certain embodiments, the crystalline form of a substance may be physically and / or chemically pure. In certain embodiments, a crystalline form of a substance may be about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91% or 90% physically and / or chemically pure.

[0030] Crystalline forms of a substance can be obtained by several methods, including, but not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces (such as in nanopores or capillaries), recrystallization on a surface or template (such as on a polymer), recrystallization in the presence of additives (such as co-crystal pair molecules), desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, grinding, and solvent drop grinding.

[0031] Unless otherwise specified, the terms "polymorph" and "polymorphic form" and related terms herein refer to two or more crystalline forms of essentially the same molecules or ions. As with different crystalline forms, different polymorphs may have different physical properties, such as melting temperature, heat of fusion, solubility, dissolution rate, and / or vibrational spectrum, as a result of different arrangements or conformations of molecules or ions within the crystal lattice. The differences in physical properties exhibited by polymorphs may affect pharmaceutical parameters, such as storage stability, compressibility and density (important in the manufacture of formulations and products) and dissolution rate (an important factor in bioavailability). Differences in stability may be due to changes in chemical reactivity (e.g., differences in oxidation such that a dosage form containing one polymorph discolors more quickly than one containing another polymorph) or mechanical changes (e.g., tablets crumble on storage because a kinetically favored polymorph changes to a thermodynamically more stable polymorph), or both (e.g., tablets of one polymorph are more susceptible to breakage at high humidity). As a result of solubility / dissolution differences, at one extreme some polymorphic transformations may result in loss of efficacy and at the other extreme toxicity. Additionally, the physical properties of the crystals may be important in processing (e.g. one polymorph may be more likely to form solvates or may be difficult to filter and wash free of impurities, particle shape and size distribution may differ between polymorphs).

[0032] As used herein and unless otherwise specified, the terms "amorphous", "amorphous form" and related terms as used herein mean that the substance, component or product in question is substantially not crystalline as determined by X-ray diffraction. In particular, the term "amorphous form" describes a disordered solid form, i.e., a solid form lacking long-range crystalline order. In certain embodiments, an amorphous form of a substance may be substantially free of other amorphous and / or crystalline forms. In other embodiments, an amorphous form of a substance may contain less than about 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of one or more other amorphous and / or crystalline forms. In certain embodiments, an amorphous form of a substance may be physically and / or chemically pure. In certain embodiments, the amorphous form of the substance may be about 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% physically and / or chemically pure. In certain embodiments, the amorphous form of the substance may include additional components or ingredients (e.g., additives, polymers, or excipients that may serve to further stabilize the amorphous form). In certain embodiments, the amorphous form may be a solid solution.

[0033] Amorphous forms of substances can be obtained by several methods, including, but not limited to, heating, melt cooling, rapid melt cooling, solvent evaporation, rapid solvent evaporation, desolvation, sublimation, grinding, ball milling, cryogenic grinding, spray drying, and freeze drying.

[0034] Techniques for characterizing crystalline and amorphous forms include, but are not limited to, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), X-ray powder diffractometry (XRPD), single crystal X-ray diffraction, vibrational spectroscopy such as infrared (IR) and Raman spectroscopy, solid-state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility measurements, dissolution measurements, elemental analysis, and Karl Fischer analysis. Characteristic unit cell parameters can be determined using one or more techniques, such as, but not limited to, X-ray diffraction and neutron diffraction, including single crystal diffraction and powder diffraction. Techniques useful for analyzing powder diffraction data include profile refinement, such as, for example, Rietveld refinement, which can be used to analyze diffraction peaks associated with a single phase in a sample containing two or more solid phases. Other methods useful for analyzing powder diffraction data include unit cell indexing, which allows one of skill in the art to determine unit cell parameters from samples that include crystalline powders.

[0035] A solid form may exhibit distinct physical characterization data that is specific to a particular solid form, such as the crystalline forms provided herein. These characterization data may be obtained by a variety of techniques known to those skilled in the art, including, for example, X-ray powder diffraction, differential scanning calorimetry, thermogravimetry, and nuclear magnetic resonance spectroscopy. The data provided by these techniques may be used to identify a particular solid form. A person skilled in the art may determine whether a solid form is one of the forms provided herein by performing one of these characterization techniques and determining whether the data obtained "matches" the reference data provided herein that are identified as being characteristic of a particular solid form. Characterization data that "matches" that of a reference solid form is understood by those skilled in the art to represent the same solid form as the reference solid form. When analyzing whether data "matches", it is understood by those skilled in the art that a particular characterization data point may vary to a reasonable extent, for example due to experimental error and routine sample-to-sample analytical variability, but may still describe a given solid form.

[0036] As used herein, and unless otherwise stated, terms such as "halo" or "halogen" mean -F, -Cl, -Br, or -I.

[0037] As used herein and unless otherwise stated, the term "alkyl" refers to an unbranched or branched saturated monovalent hydrocarbon chain. Examples of alkyl groups include (C1-C6) alkyl groups, such as, but not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl. Longer alkyl groups include heptyl, octyl, nonyl, and decyl groups. An alkyl group can be unsubstituted or substituted with one or more suitable substituents. An alkyl group can also be an isotopologue of a natural abundance alkyl group by being enriched with carbon and / or hydrogen (i.e., deuterium or tritium) isotopes. As used herein and unless otherwise stated, the term "alkenyl" refers to an unbranched or branched monovalent hydrocarbon chain containing one or more carbon-carbon double bonds. As used herein and unless otherwise stated, the term "alkynyl" refers to an unbranched or branched monovalent hydrocarbon chain containing one or more carbon-carbon triple bonds.

[0038] As used herein and unless otherwise stated, the term "alkoxy" refers to an alkyl group linked to another group via an oxygen atom (i.e., -O-alkyl). An alkoxy group can be unsubstituted or substituted with one or more suitable substituents. Examples of alkoxy groups include -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, -O-2-methyl-1-propyl, -O-2-methyl-2-propyl, -O-2-methyl-1-butyl, -O-3-methyl-1-butyl, -O-2-methyl-3-butyl, -O-2,2-dimethyl-1-propyl, -O-2-methyl-1-pentyl, 3-O-methyl-1-pentyl, -O-4-methyl-1-pentyl, -O- Examples of (C1-C6)alkoxy groups include, but are not limited to, 2-methyl-2-pentyl, -O-3-methyl-2-pentyl, -O-4-methyl-2-pentyl, -O-2,2-dimethyl-1-butyl, -O-3,3-dimethyl-1-butyl, -O-2-ethyl-1-butyl, -O-butyl, -O-isobutyl, -Ot-butyl, -O-pentyl, -O-isopentyl, -O-neopentyl, and -O-hexyl. Longer alkoxy groups include -O-heptyl, -O-octyl, -O-nonyl, and -O-decyl groups. Alkoxy groups can also be isotopologues of natural abundance alkoxy groups by being enriched with isotopes of carbon, oxygen, and / or hydrogen (i.e., deuterium or tritium).

[0039] As used herein and unless otherwise specified, the term "cycloalkyl" or "carbocyclyl" refers to a type of alkyl that is cyclic and contains 3 to 15, 3 to 9, 3 to 6, or 3 to 5 carbon atoms that do not contain alternating or resonating double bonds between the carbon atoms. It may contain 1 to 4 rings. Examples of unsubstituted cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Cycloalkyls may be substituted with one or more substituents. In some embodiments, cycloalkyls may be fused to an aryl or heteroaryl group.

[0040] As used herein and unless otherwise specified, the term "heterocycloalkyl" or "heterocyclyl" refers to a cycloalkyl in which one or more, in some embodiments one to three, carbon atoms are replaced by a heteroatom, such as, but not limited to, N, S, and O. In some embodiments, the heterocycloalkyl group contains 3 to 15, 3 to 9, 3 to 6, or 3 to 5 carbon and heteroatoms. In some embodiments, the heterocycloalkyl can be a heterocycloalkyl fused to an aryl or heteroaryl group. 3~6 When a prefix such as is used to refer to a heterocycloalkyl group, it means that the number of carbons (in this example, 3-6) also includes the heteroatom. For example, C 3~6 Heterocycloalkyl groups are meant to include, for example, tetrahydropyranyl (5 carbon atoms and 1 heteroatom replacing a carbon atom).

[0041] As used herein and unless otherwise specified, the term "aryl" refers to a carbocyclic aromatic ring containing 5 to 14 ring atoms. The ring atoms of a carbocyclic aryl group are all carbon atoms. Aryl ring structures include monocyclic, bicyclic, or tricyclic compounds and compounds having one or more ring structures, such as benzo-fused carbocyclic moieties, e.g., 5,6,7,8-tetrahydronaphthyl. In particular, aryl groups can be monocyclic, bicyclic, or tricyclic rings. Representative aryl groups include phenyl, anthracenyl, fluorenyl, indenyl, azulenyl, phenanthrenyl, and naphthyl.

[0042] As used herein and unless otherwise specified, the term "heteroaryl" refers, in certain embodiments, to a monocyclic or polycyclic aromatic ring group having about 5 to about 15 members, in which one or more, in some embodiments one to three, of the atoms in the ring group are heteroatoms, i.e., elements other than carbon, including but not limited to N, O, or S. The heteroaryl group may be optionally fused to a benzene ring. Heteroaryl groups include, but are not limited to, furyl, imidazolyl, indolinyl, pyrrolidinyl, pyrimidinyl, tetrazolyl, thienyl, pyridyl, pyrrolyl, N-methylpyrrolyl, quinolinyl, and isoquinolinyl.

[0043] As used herein and unless otherwise stated, the term "alcohol" refers to any compound substituted with an -OH group. The alcohol group may also be an isotopologue of the natural abundance alcohol group by being enriched with isotopes of oxygen and / or hydrogen (i.e., deuterium or tritium).

[0044] As used herein and unless otherwise stated, the term "amino" or "amino group" means a monovalent group of formula -NH, -NH(alkyl), -NH(aryl), -N(alkyl), -N(aryl), or -N(alkyl)(aryl). Amino groups can also be isotopologues of natural abundance amino groups by being enriched with carbon, nitrogen, and / or hydrogen (i.e., deuterium or tritium) isotopes.

[0045] Unless otherwise stated, the compounds provided herein, including intermediates useful for the preparation of the compounds provided herein, containing reactive functional groups (such as, but not limited to, carboxy, hydroxy, and amino moieties), also include protected derivatives thereof. A "protected derivative" is a compound in which a reactive site or sites are blocked with one or more protecting groups (also known as blocking groups). Suitable protecting groups for carboxy moieties include benzyl, t-butyl, and the like, and their isotopologues. Suitable protecting groups for amino and amide groups include acetyl, trifluoroacetyl, t-butyloxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for hydroxy include benzyl, and the like. Other suitable protecting groups are well known to those skilled in the art. The selection and use of protecting groups, as well as the reaction conditions for introducing and removing protecting groups, are described in Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley & Sons, New York, 2007, which is incorporated herein by reference in its entirety.

[0046] Amino protecting groups known in the art include those described in detail in TW Green, Protective Groups in Organic Synthesis. Amino protecting groups include -OH, -OR aa , -N(R cc )2, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR cc )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SRcc , C 1~10 Alkyl (e.g., aralkyl groups), C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R aa Each instance of 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 aryl and 5- to 14-membered heteroaryl, each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently having 0, 1, 2, 3, 4, or 5 R dd substituted with a group; R bb Each instance of is independently hydrogen, -OH, -OR aa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)2N(Rcc )2, -P(=O)(NR cc )2, C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 aryl and 5-14 membered heteroaryl, or two R bonded to the N atom cc groups are linked to form a 3- to 14-membered heterocyclyl or a 5- to 14-membered heteroaryl ring, and each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd The group is substituted. R cc Each instance of is independently hydrogen, C 1~10 Alkyl, C 1~10 Perhaloalkyl, C 2~10 Alkenyl, C 2~10 Alkynyl, C 3~10 Carbocyclyl, 3-14 membered heterocyclyl, C 6~14 aryl and 5-14 membered heteroaryl, or two R bonded to the N atom cc groups are linked to form a 3- to 14-membered heterocyclyl or a 5- to 14-membered heteroaryl ring, and each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R dd The group is substituted. R dd Each example is independently a halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee , -ON(R ff )2, -N(R ff )2, -N(R ff )3 + X - , -N(OR ee )R ff , -SH, -SR ee , -SSR ee , -C(=O)R ee , -CO2H, -CO2Ree , -OC(=O)R ee , -OCO2R ee , -C(=O)N(R ff )2, -OC(=O)N(R ff )2, -NR ff C(=O)R ee , -NR ff CO2R ee , -NR ff C(=O)N(R ff )2, -C(=NR ff ) OR ee , -OC(=NR ff )R ee , -OC(=NR ff ) OR ee , -C(=NR ff )N(R ff )2, -OC(=NR ff )N(R ff )2, -NR ff C(=NR ff )N(R ff )2, -NR ff SO2R ee , -SO2N(R ff )2, -SO2R ee , -SO2OR ee , -OSO2R ee , -S(=O)R ee , -Si(R ee )3, -OSi(R ee )3, -C(=S)N(R ff )2, -C(=O)SR ee , -C(=S)SR ee , -SC(=S)SR ee , -P(=O)2R ee , -P(=O)(R ee )2, -OP(=O)(R ee )2, -OP(=O)(OR ee )2, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~10 Carbocyclyl, 3-10 membered heterocyclyl, C 6~10aryl, and 5- to 10-membered heteroaryl, each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently being selected from 0, 1, 2, 3, 4, or 5 R gg or two geminal R dd The substituents may be linked to form =O or =S. R ee Each instance of 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, and 3- to 10-membered heteroaryl, each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently having 0, 1, 2, 3, 4, or 5 R gg substituted with a group; R ff Each instance of is independently hydrogen, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~10 Carbocyclyl, 3-10 membered heterocyclyl, C 6~10 aryl and 5-10 membered heteroaryl, or two R bonded to the N atom ff groups are linked to form a 3- to 14-membered heterocyclyl or a 5- to 14-membered heteroaryl ring, and each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl independently has 0, 1, 2, 3, 4, or 5 R gg substituted with a group; and R gg Each example is independently a halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1~6 Alkyl, -ON(C 1~6 alkyl)2, -N(C 1~6 alkyl)2, -N(C 1~6 alkyl)3X, -NH(C 1~6alkyl)2X, -NH2(C 1~6 Alkyl)X, -NH3X, -N(OC 1~6 Alkyl)(C 1~6 alkyl), -N(OH)(C 1~6 alkyl), -NH(OH), -SH, -SC 1~6 Alkyl, -SS(C 1~6 alkyl), -C(=O)(C 1~6 alkyl), -CO2H, -CO2(C 1~6 alkyl), -OC(=O)(C 1~6 alkyl), -OCO2(C 1~6 alkyl), -C(=O)NH2, -C(=O)N(C 1~6 alkyl)2, -OC(=O)NH(C 1~6 alkyl), -NHC(=O)(C 1~6 alkyl), -N(C 1~6 Alkyl)C(=O)(C 1~6 alkyl), -NHCO2(C 1~6 alkyl), -NHC(=O)N(C 1~6 alkyl)2, -NHC(=O)NH(C 1~6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1~6 alkyl), -OC(=NH)(C 1~6 alkyl), -OC(=NH)OC 1~6 Alkyl, -C(=NH)N(C 1~6 alkyl)2, -C(=NH)NH(C 1~6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1~6 alkyl)2, -OC(NH)NH(C 1~6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1~6 alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1~6 Alkyl), -SO2N(C 1~6 Alkyl)2, -SO2NH(C 1~6 Alkyl), -SO2NH2, -SO2C 1~6 Alkyl, -SO2OC 1~6 Alkyl, -OSO2C 1~6 Alkyl, -SOC 1~6 Alkyl, -Si(C 1~6alkyl)3, -OSi(C 1~6 Alkyl)3-C(=S)N(C 1~6 alkyl)2, C(=S)NH(C 1~6 alkyl), C(=S)NH2, -C(=O)S(C 1~6 Alkyl), -C(=S)SC 1~6 Alkyl, -SC(=S)SC 1~6 Alkyl, -P(=O)2(C 1~6 alkyl), -P(=O)(C 1~6 alkyl)2, -OP(=O)(C 1~6 Alkyl)2, -OP(=O)(OC 1~6 Alkyl)2, C 1~6 Alkyl, C 1~6 Perhaloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~10 Carbocyclyl, C 6~10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl; or two geminal R gg the substituents may be linked to form =O or =S; X - is the counter ion.

[0047] As used herein, a "counterion" is a negatively charged group that associates with a positively charged quaternary amine to maintain electronic neutrality. Exemplary counterions include halide ions (e.g., F - , Cl - , Br - , I - ), NO3 - , ClO4 - , O.H. - , H2PO4 - , HSO4 -, sulfonates (e.g., methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, 10-camphorsulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1-sulfonic acid-5-sulfonic acid, ethane-1-sulfonic acid-2-sulfonic acid, etc.) and carboxylates (e.g., acetate, ethanoic acid, propanoic acid, benzoic acid, glyceric acid, lactate, tartaric acid, glycolic acid, etc.). Counterions also include chiral counterions, some of which may be useful for chiral resolution of racemic mixtures. Exemplary chiral counterions include (S)-(+) mandelic acid, (D)-(+) tartaric acid, (+) 2,3-dibenzoyl-D-tartaric acid, N-acetyl-L-leucine, and N-acetyl-L-phenylalanine.

[0048] For example, an amide group (e.g., -C(=O)R aa Amino protecting groups such as acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzyloxycarbonylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinamide, N-acetylmethionine derivatives, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.

[0049] Carbamate groups (e.g., -C(=O)OR aaAmino protecting groups such as methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthy]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylphenylcarbamate (Tm ... Tylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t -Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkenyl carbamate, Kyldithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrilebenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzoisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chloro Monyl methyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl (o-nitrophenyl) methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropyl methyl carbamate, p-decyloxybenzyl carbamate, 2, 2-Dimethoxycarbonylvinylcarbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isobolinyl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate , 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate and 2,4,Examples include, but are not limited to, 6-trimethylbenzyl carbamate.

[0050] Sulfonamide groups (e.g., -S(=O)R aa ) and other amino protecting groups include p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts) , 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide and phenacylsulfonamide.

[0051] Other amino protecting groups include phenothiazinyl-(10)-carbonyl derivatives, N'-p-toluenesulfonylaminocarbonyl derivatives, N'-phenylaminothiocarbonyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, and N-1,1,4,4-tetramethyldisilyl. Azacyclopentane adducts (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-ones, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-ones, 1-substituted 3,5-dinitro-4-pyridones, N-methylamines, N-allylamines, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrololine-3-yl)amine, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrololine-3-yl)amine, N-methyl ... )amine, quaternary ammonium salt, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N'-oxide, N-1,1-dimethylthio Omethyleneamine, N-benzylideneamine, Np-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine, Np-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-Dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivatives, N-diphenylborinic acid derivatives, N-[phenyl(pentacarbonylchromium- or tungsten)carbonyl]amine, N-copper chelates, N-zinc chelates, N-nitroamines, N-nitrosamines, amine N-oxides, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidates, diphenyl phosphoramidates, benzenesulfenamides, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide and 3-nitropyridine sulfenamide (Npys).

[0052] As used herein and unless otherwise stated, the term "hydroxyl protecting group" refers to a protecting group suitable for preventing undesired reactions at a hydroxyl group. Examples of hydroxyl protecting groups include, but are not limited to, allyl, methyl, 2-methoxyethoxymethyl (MEM), methoxymethyl (MOM), methoxythiomethyl, t-butoxymethyl, tri-isopropylsilyloxymethyl (TOM), ethyl, 1-ethoxyethyl, isopropyl, t-butyl, benzyl, trityl (Tr), dimethoxytrityl (DMT), monomethoxytrityl (MMT), p-methoxybenzyl (PMB), acetyl, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl (Piv), benzoyl, p-phenylbenzoyl, trimethylsilyl (TMS), triisopropylsilyl (TIPS), t-butyldimethylsilyl (TBDMS) and tetrahydropyranyl. Additional examples of hydroxyl protecting groups are described in Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley & Sons, New York, 2007, which is incorporated herein by reference in its entirety.

[0053] As used herein and unless otherwise stated, acronyms or symbols for groups or reagents have the following definitions: HPLC = high performance liquid chromatography; THF = tetrahydrofuran; CH3CN = acetonitrile; HOAc = acetic acid; DCM = dichloromethane; IPA = isopropyl alcohol; MTBE = methyl tert-butyl ether, CPME = cyclopentyl methyl ether; DMF = dimethylformamide; NMP = N-methyl-2-pyrrolidone; EtOAc = ethyl acetate; MsCl = mesyl chloride; DIEA = diisopropylethylamine; TEA = triethylamine.

[0054] As used herein, and unless otherwise stated, the terms "substituted" or "substituted", when used to describe chemical structures or moieties, include, but are not limited to, alkyl, alkenyl, alkynyl, and cycloalkyl; alkoxyalkyl; aroyl; halo; haloalkyl (e.g., trifluoromethyl); heterocycloalkyl; haloalkoxy (e.g., trifluoromethoxy); hydroxy; alkoxy; cycloalkyloxy; heterosiloxy; oxo; alkanoyl; aryl; heteroaryl (e.g., indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, and pyrimidyl); arylalkyl; alkylaryl; heteroaryl; heteroarylalkyl; alkylheteroaryl; heterocyclo; heterocycloalkyl-alkyl; aryloxy, alkanoyloxy; amino; alkylamino; arylamino; aryl It refers to derivatives of the structure or moiety in which one or more of its hydrogen atoms have been replaced by a substituent such as alkylamino; cycloalkylamino; heterocycloamino; mono- and di-substituted amino; alkanoylamino; aroylamino; aralkanoylamino; aminoalkyl; carbamyl (e.g., CONH2); substituted carbamyl (e.g., CONH-alkyl, CONH-aryl, CONH-arylalkyl, or when there are two substituents on the nitrogen); carbonyl; alkoxycarbonyl; carboxy; cyano; ester; ether; guanidino; nitro; sulfonyl; alkylsulfonyl; arylsulfonyl; arylalkylsulfonyl; sulfonamide (e.g., SO2NH2); substituted sulfonamide; thiol; alkylthio; arylthio; arylalkylthio; cycloalkylthio; heterocyclothio; alkylthiono; arylthiono; and arylalkylthiono. In some embodiments, the substituent may itself be substituted with one or more chemical moieties, such as, but not limited to, those described herein.

[0055] As used herein, and unless otherwise stated, the terms "about" and "approximately" are used to specify that a given value is an approximation. For example, the term "about" when used in relation to reaction temperature indicates that the indicated temperature includes a temperature deviation of within 30%, 25%, 20%, 15%, 10%, or 5%. Similarly, the term "about" when used in relation to reaction time indicates that the indicated time period includes a time period deviation of within 30%, 25%, 20%, 15%, 10%, or 5%.

[0056] As used herein, and unless otherwise specified, the terms "about" and "approximately" when used in connection with a numerical value or range of values ​​provided to characterize a particular solid form, such as a specific temperature or temperature range, such as those describing a melting temperature, dehydration temperature, desolvation temperature, or glass transition temperature; mass change, such as mass change as a function of temperature or humidity; solvent or water content, such as by mass or percentage; or peak position, such as in an analysis by IR or Raman spectroscopy or XRPD, indicate that the value or range of values ​​may deviate to an extent that would be considered reasonable by a person skilled in the art, but still describe the particular solid form. For example, in certain embodiments, the terms "about" and "approximately" when used in this context indicate that the numerical value or range of values ​​may vary within 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the stated value or range of values. For example, in some embodiments, XRPD peak position values ​​may vary by up to ±0.2 degrees 2θ, but still describe a particular XRPD peak. In one embodiment, XRPD peak position values ​​may vary by up to ±0.1 degrees 2θ. As used herein, a tilde (i.e., "~") preceding a numerical value or range of values ​​indicates "about" or "approximately."

[0057] As used herein, and unless otherwise stated, the term "hydrogenation" refers to the chemical process of adding a hydrogen atom to an unsaturated bond.

[0058] As used herein and unless otherwise stated, an "isotopologue" is an isotopically enriched compound. The term "isotopically enriched" refers to an atom that has an isotopic composition other than the natural isotopic composition of that atom. "Isotopically enriched" can also refer to a compound that contains at least one atom that has an isotopic composition other than the natural isotopic composition of that atom. The term "isotopic composition" refers to the amount of each isotope present for a given atom, and "natural isotopic composition" refers to the naturally occurring isotopic composition or abundance for a given atom.

[0059] The present disclosure can be more fully understood by reference to the following detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments.

[0060] Although most of the embodiments and examples provided herein relate to the (S)-enantiomer of a compound, it is to be understood that when the stereochemistry of a chiral reactant, reagent, solvent, catalyst, ligand, or the like is inverted, the corresponding (R)-enantiomer of the compound can be prepared by the methods provided.

[0061] 6.2 Method In some embodiments, the present specification provides a compound of formula (I): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologues thereof, comprising the steps of: (Step 1.0) Formula (II): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof to provide a compound of formula (I) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof; (Step 1.1) Optionally, converting a compound of formula (I) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof into a salt of the compound; A method is provided that includes:

[0062] In some embodiments, step 1.0 is performed in the presence of an acid. In some embodiments, step 1.0 is performed in the presence of an inorganic acid. In some embodiments, step 1.0 is performed in the presence of hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid. In one embodiment, step 1.0 is performed in the presence of hydrochloric acid.

[0063] In some embodiments, step 1.0 is carried out in the presence of an organic acid. b COOH(in the formula, R b is hydrogen, substituted or unsubstituted C 1~10 Alkyl, substituted or unsubstituted C 1~10 Haloalkyl or substituted or unsubstituted C 5~14 aryl). In some embodiments, step 1.0 is performed in the presence of formic acid, acetic acid, trifluoroacetic acid, or benzoic acid.

[0064] In some embodiments, step 1.0 comprises: b SO3H (in the formula, R b is hydrogen, substituted or unsubstituted C 1~10 Alkyl, substituted or unsubstituted C 1~10 Haloalkyl or substituted or unsubstituted C 5~14 aryl). In some embodiments, step 1.0 is performed in the presence of sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, or trifluoromethanesulfonic acid. In one embodiment, step 1.0 is performed in the presence of benzenesulfonic acid.

[0065] In some embodiments, the compound of formula (I) or its salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue prepared in step 1.0 is a salt of the compound of formula (I). In some embodiments, the salt of the compound of formula (I) can be produced by protonation of one or more of its nitrogen atoms. In some embodiments, the salt of the compound of formula (I) can be the chloride, bromide, iodide, sulfate, nitrate, acetate, formate, trifluoroacetate, benzoate, sulfonate, besylate, tosylate, camphorsulfonate, mesylate or triflate salt of the compound of formula (I). In one embodiment, the besylate salt of the compound of formula (I) is prepared in step 1.0. In one embodiment, the besylate salt is a bisbesylate salt.

[0066] In some embodiments, the molar ratio of the compound of Formula (II) to the acid is about 1:4 to about 1:7. In one embodiment, the molar ratio of the compound of Formula (II) to the acid is about 1:5.5.

[0067] Step 1.0 may be carried out in a solvent suitable for the cyclization reaction. In some embodiments, the solvent is diethyl ether, methyl tert-butyl ether, cyclopentyl methyl ether, 1,4-dioxane, tetrahydrofuran, methyl tetrahydrofuran, ethyl acetate, isopropyl acetate, acetonitrile, methanol, ethanol, isopropyl alcohol, water, dichloromethane, dimethylformamide, dimethylsulfoxide, glyme, diglyme, dimethylacetamide, or N-methyl-2-pyrrolidone, or a mixture thereof. In one embodiment, the solvent is acetonitrile. In another embodiment, the solvent is a mixture of acetonitrile and methyl tert-butyl ether. In yet another embodiment, the solvent is a mixture of acetonitrile and isopropyl acetate. In yet another embodiment, the solvent is a mixture of acetonitrile, methyl tetrahydrofuran, and optionally water.

[0068] In some embodiments, only a stoichiometric amount of water is added. In some embodiments, the molar ratio of the compound of formula (II) to water is about 1:1 to about 1:3. In one embodiment, the molar ratio of the compound of formula (II) to water is 1:2.

[0069] Step 1.0 may be carried out at a reaction temperature suitable for the cyclization reaction. In some embodiments, the reaction temperature is from about 20° C. to about 100° C. In some embodiments, step 1.0 is carried out at the reflux temperature of the solvent. In one embodiment, the reaction temperature is about 55° C.

[0070] In some embodiments, the reaction time for step 1.0 is from about 10 hours to about 20 hours, hi one embodiment, the reaction time is about 16 hours.

[0071] In one embodiment, step 1.0 is carried out in the presence of benzenesulfonic acid and the solvent is a mixture of acetonitrile and methyltetrahydrofuran to prepare the bisbesylate salt of the compound of formula (I).

[0072] In some embodiments, in step 1.1, the compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, is converted to a different salt of the compound. In one embodiment, the compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, is converted to the hydrochloride salt of the compound.

[0073] In some embodiments, in step 1.1, the salt of the compound of Formula (I) is contacted with a basic aqueous solution, which is subsequently acidified. In some embodiments, the basic aqueous solution comprises a bicarbonate solution. In some embodiments, the acidification comprises adding hydrochloric acid or a solution thereof.

[0074] In some embodiments, step 1.1 is carried out in a biphasic mixture comprising an aqueous solution and an organic solvent. In some embodiments, the organic solvent is diethyl ether, methyl tert-butyl ether, cyclopentyl methyl ether, 1,4-dioxane, tetrahydrofuran, methyltetrahydrofuran, ethyl acetate, isopropyl acetate, acetonitrile, methanol, ethanol, isopropyl alcohol, dichloromethane, dimethylformamide, dimethylsulfoxide, glyme, diglyme, dimethylacetamide, or N-methyl-2-pyrrolidone, or a mixture thereof. In one embodiment, the organic solvent is methyltetrahydrofuran. In another embodiment, the organic solvent is a mixture of ethyl acetate or isopropyl alcohol.

[0075] In some embodiments, step 1.1 is carried out at a reaction temperature of about 0° C. to about 25° C. In one embodiment, the reaction temperature is about 15° C.

[0076] In one embodiment of step 1.1, the bisbesylate salt of the compound of formula (I) is converted to the hydrochloride salt of the compound of formula (I). In one embodiment, the bisbesylate salt (e.g., in a solvent of a mixture of ethyl acetate or isopropyl alcohol) is neutralized or basified by the addition of aqueous potassium bicarbonate and then acidified by the addition of hydrochloric acid to provide the hydrochloride salt. In one embodiment, the hydrochloride salt undergoes further wet-milling and / or co-milling.

[0077] In some embodiments, provided herein is a process for preparing a compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 2.a) Formula (II-A): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof with 4-(azetidin-3-yl)morpholine or a salt thereof. A method is provided that includes:

[0078] In some embodiments, a salt of 4-(azetidin-3-yl)morpholine is used as one of the starting materials in step 2.a. In one embodiment, the hydrochloride salt of 4-(azetidin-3-yl)morpholine is used.

[0079] In some embodiments, the molar ratio of the compound of formula (II-A) to 4-(azetidin-3-yl)morpholine or a salt thereof is about 2:1 to about 1:2. In one embodiment, the molar ratio of the compound of formula (II-A) to 4-(azetidin-3-yl)morpholine or a salt thereof is about 1:1.

[0080] In some embodiments, step 2.a is performed in the presence of a base. In some embodiments, step 2.a is performed in the presence of a nitrogen-containing base. In some embodiments, step 2.a is performed in the presence of NH4OH, triethylamine, diisopropylethylamine (DIEA), pyridine, lutidine, 4-dimethylaminopyridine, imidazole, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). In one embodiment, the base is diisopropylethylamine (DIEA).

[0081] In some embodiments, the molar ratio of the compound of Formula (II-A) to the base is about 1:2 to about 1:4. In one embodiment, the molar ratio of the compound of Formula (II-A) to the base is about 1:3.

[0082] Step 2.a may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is dimethylsulfoxide.

[0083] In some embodiments, step 2.a is carried out at a reaction temperature of about 0° C. to about 40° C. In one embodiment, the reaction temperature is about 30° C.

[0084] In some embodiments, step 2.a is carried out for a reaction time of about 8 hours to about 24 hours, hi one embodiment, the reaction time is about 16 hours.

[0085] In one embodiment, the compound of formula (II-A) is reacted with the hydrochloride salt of 4-(azetidin-3-yl)morpholine in the presence of diisopropylethylamine as a base, the molar ratio of the compound of formula (II-A) to 4-(azetidin-3-yl)morpholine is about 1:1, the molar ratio of the compound of formula (II-A) to the base is about 1:3, and the solvent is dimethylsulfoxide. In one embodiment, the reaction temperature is about 30° C., and the reaction time is about 16 hours. In one embodiment, the compound of formula (II) is purified by selective extraction in ethyl acetate followed by chromatographic separation using silica gel.

[0086] In some embodiments, provided herein is a process for the preparation of a compound of formula (II-A), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 2.b) Formula (II-B): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof. A method is provided that includes:

[0087] Step 2.b may be carried out in the presence of any chlorinating reagent suitable for chlorination. In some embodiments, the chlorinating reagent is thionyl chloride, oxalyl chloride, phosphorus trichloride or mesyl chloride (MsCl). In one embodiment, the chlorinating reagent is mesyl chloride (MsCl).

[0088] In some embodiments, the molar ratio of the compound of formula (II-B) to the chlorinating reagent is about 1:1 to about 1:3. In one embodiment, the molar ratio of the compound of formula (II-B) to the chlorinating reagent is about 1:2.

[0089] In some embodiments, step 2.b. is carried out in the presence of a base. In some embodiments, step 2.b. is carried out in the presence of a nitrogen-containing base. In some embodiments, the base is NH4OH, triethylamine, diisopropylethylamine (DIEA), pyridine, 4-dimethylaminopyridine, imidazole, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). In one embodiment, the base is diisopropylethylamine (DIEA).

[0090] In some embodiments, the molar ratio of the compound of Formula (II-B) to the base is about 1:2 to about 1:4. In one embodiment, the molar ratio of the compound of Formula (II-B) to the base is about 1:3.

[0091] Step 2.b may be carried out in a suitable solvent for the reaction. In one embodiment, the solvent is N-methyl-2-pyrrolidone.

[0092] In some embodiments, step 2.b is carried out at a reaction temperature of about −5° C. to about 40° C. In one embodiment, the reaction temperature is about 30° C.

[0093] In some embodiments, step 2.b is carried out for a reaction time of about 6 hours to about 24 hours, hi one embodiment, the reaction time is about 12 hours.

[0094] In one embodiment, the compound of formula (II-B) is reacted with mesyl chloride in the presence of diisopropylethylamine as a base, the molar ratio of the compound of formula (II-B) to mesyl chloride is about 1:2, the molar ratio of the compound of formula (II-B) to the base is about 1:3, and the solvent is N-methyl-2-pyrrolidone. In one embodiment, the reaction temperature is about 30° C. and the reaction time is about 12 hours. In one embodiment, the compound of formula (II-A) is purified by selective extraction in methyl tert-butyl ether followed by chromatographic separation using silica gel.

[0095] In some embodiments, provided herein is a process for the preparation of a compound of formula (II-B), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 2.c) Formula (V): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof with 2-fluoro-4-(hydroxymethyl)benzaldehyde. A method is provided that includes:

[0096] In some embodiments, the molar ratio of the compound of formula (V) to 2-fluoro-4-(hydroxymethyl)benzaldehyde is about 1:1 to about 1:2. In one embodiment, the molar ratio of the compound of formula (V) to 2-fluoro-4-(hydroxymethyl)benzaldehyde is about 1:1.3.

[0097] In some embodiments, step 2.c is performed in the presence of a reducing agent. In some embodiments, the reducing agent is a borohydride reagent. In some embodiments, the borohydride reagent is sodium borohydride, sodium tri(acetoxy)borohydride, or sodium cyanoborohydride. In one embodiment, the borohydride reagent is sodium cyanoborohydride.

[0098] In some embodiments, the molar ratio of the compound of Formula (V) to the reducing agent is about 1:1 to about 1:3. In one embodiment, the molar ratio of the compound of Formula (V) to the reducing agent is about 1:1.5.

[0099] In some embodiments, step 2.c is performed in the presence of a catalyst. In some embodiments, step 2.c is performed in the presence of an acid catalyst. In some embodiments, step 2.c is performed in the presence of a Lewis acid catalyst. In some embodiments, the Lewis acid catalyst is titanium tetra(isopropoxide) or zinc dichloride. In other embodiments, step 2.c is performed in the presence of a Bronsted acid catalyst. In some embodiments, the Bronsted acid catalyst is an organic acid. In some embodiments, the organic acid is R b Carboxylic acids in the form COOH and R b is hydrogen, substituted or unsubstituted C 1~10 Alkyl, substituted or unsubstituted C 1~10 Haloalkyl or substituted or unsubstituted C 5~14 aryl. In some embodiments, the Bronsted acid catalyst is formic acid, acetic acid, trifluoroacetic acid, or benzoic acid. In one embodiment, step 2.c is performed in the presence of trifluoroacetic acid.

[0100] In some embodiments, the molar ratio of the compound of Formula (V) to the catalyst is about 1:4 to about 1:6. In one embodiment, the molar ratio of the compound of Formula (V) to the catalyst is about 1:5.

[0101] Step 2.c may be carried out in a suitable solvent for the reaction. In one embodiment, the solvent is dichloromethane.

[0102] In some embodiments, step 2.c is carried out at a reaction temperature of about −5° C. to about 40° C. In one embodiment, the reaction temperature is about 30° C.

[0103] In some embodiments, step 2.c is carried out for a reaction time of about 0.5 hours to about 5 hours, hi one embodiment, the reaction time is about 2.5 hours.

[0104] In one embodiment, the compound of formula (V) is reacted with 2-fluoro-4-(hydroxymethyl)benzaldehyde and sodium cyanoborohydride in the presence of trifluoroacetic acid as a catalyst, the molar ratio of the compound of formula (V) to 2-fluoro-4-(hydroxymethyl)benzaldehyde is about 1:1.3, the molar ratio of the compound of formula (V) to sodium cyanoborohydride is about 1:1.5, the molar ratio of the compound of formula (V) to trifluoroacetic acid is about 1:5, and the solvent is dichloromethane. In one embodiment, the reaction temperature is about 30° C., and the reaction time is about 2.5 hours. In one embodiment, the compound of formula (II-B) is purified by quenching with methanol followed by chromatographic separation using silica gel.

[0105] In some embodiments, provided herein is a process for the preparation of a compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 2.0) Formula (III): [ka] or a salt, solvate, hydrate or isotopologue thereof, of formula (V): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof. A method is provided that includes:

[0106] In some embodiments, a salt of the compound of formula (III) is used in step 2.0. In one embodiment, the salt is a hydrochloride salt. In one embodiment, the salt is an oxalate salt. In one embodiment, the salt is a bis-oxalate salt. In one embodiment, the salt is a bis-hydrochloride salt.

[0107] In some embodiments, the molar ratio of the compound of formula (V) to the compound of formula (III) is about 1:1 to about 1:2. In one embodiment, the molar ratio of the compound of formula (V) to the compound of formula (III) is about 1:1.2.

[0108] In some embodiments, step 2.0 is performed in the presence of a reducing agent. In some embodiments, the reducing agent is a borohydride reagent. In some embodiments, the borohydride reagent is sodium borohydride, sodium tri(acetoxy)borohydride, or sodium cyanoborohydride. In one embodiment, the borohydride reagent is sodium tri(acetoxy)borohydride.

[0109] In some embodiments, the molar ratio of the compound of Formula (V) to the reducing agent is about 1:1 to about 1:2. In one embodiment, the molar ratio of the compound of Formula (V) to the reducing agent is about 1:1.5.

[0110] In some embodiments, step 2.0 is performed in the presence of a catalyst. In some embodiments, step 2.0 is performed in the presence of an acid catalyst. In some embodiments, step 2.0 is performed in the presence of a Lewis acid catalyst. In some embodiments, the Lewis acid catalyst is titanium tetra(isopropoxide) or zinc dichloride. In other embodiments, step 2.0 is performed in the presence of a Bronsted acid catalyst. In some embodiments, the Bronsted acid catalyst is an organic acid. In some embodiments, the organic acid is R b Carboxylic acids in the form COOH and R b is hydrogen, substituted or unsubstituted C 1~10 Alkyl, substituted or unsubstituted C 1~10 Haloalkyl or substituted or unsubstituted C 5~14 aryl. In some embodiments, the Bronsted acid catalyst is formic acid, acetic acid, trifluoroacetic acid, or benzoic acid. In one embodiment, step 2.0 is performed in the presence of trifluoroacetic acid.

[0111] In some embodiments, the molar ratio of the compound of Formula (V) to the catalyst is from about 1:1 to about 1:5. In one embodiment, the molar ratio of the compound of Formula (V) to the catalyst is about 1:3.

[0112] Step 2.0 may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is acetonitrile.

[0113] In one embodiment, the compound of formula (V) is reacted with the bishydrochloride salt of the compound of formula (III) and sodium tri(acetoxy)borohydride in the presence of trifluoroacetic acid as a catalyst, and the molar ratio of the compound of formula (V) to the compound of formula (III) is about 1:1.2.

[0114] In one exemplary embodiment, the compound of formula (V) is reacted with the bis-oxalate salt of the compound of formula (III) and sodium tri(acetoxy)borohydride in the presence of trifluoroacetic acid as a catalyst, and the molar ratio of the compound of formula (V) to the compound of formula (III) is about 1:1.2.

[0115] In some embodiments, provided herein is a process for the preparation of a compound of formula (III), or a salt, solvate, hydrate, or isotopologue thereof, comprising: (Step 3.0) Formula (IV): [ka] or a salt, solvate, hydrate or isotope thereof with a formaldehyde source. A method is provided that includes:

[0116] In some embodiments, the salt of the compound of formula (IV) is first converted to the free base form of the compound of formula (IV) and then reacted with a formaldehyde source. In some embodiments, the free base form of the compound of formula (IV) is formed by contacting the salt of the compound of formula (IV) with an aqueous basic solution and optionally an organic solvent. In some embodiments, the free base form of the compound of formula (IV) is formed in situ by contacting the salt of the compound of formula (IV) with an aqueous basic solution and then reacted with a formaldehyde source without isolation. In some embodiments, the free base form of the compound of formula (IV) is purified and / or isolated prior to reaction with the formaldehyde source. In some embodiments, the aqueous basic solution is an aqueous sodium hydroxide solution. In some embodiments, the molar ratio of the compound of formula (IV) to sodium hydroxide is about 1:2.8. In some embodiments, the organic solvent is methyl tert-butyl ether.

[0117] In one embodiment, the salt of the compound of formula (IV) is the methanesulfonate salt. In one embodiment, the salt is the bismethanesulfonate salt.

[0118] Step 3.0 may be carried out in the presence of any formaldehyde source suitable for the reaction. In some embodiments, the formaldehyde source is paraformaldehyde, 1,3,5-trioxane, or dimethylformamide (DMF). In one embodiment, the formaldehyde source is dimethylformamide (DMF).

[0119] In some embodiments, the molar ratio of the compound of Formula (IV) to the formaldehyde source is about 1:1 to about 1:3. In one embodiment, the molar ratio of the compound of Formula (IV) to the formaldehyde source is about 1:1.9.

[0120] In some embodiments, step 3.0 is performed in the presence of an organometallic reagent. In some embodiments, step 3.0 is performed in the presence of an organolithium, organomagnesium, or organozinc reagent. In some embodiments, step 3.0 is performed in the presence of an organomagnesium reagent. In one embodiment, the organomagnesium reagent is iPrMgCl.LiCl.

[0121] In some embodiments, the molar ratio of the compound of Formula (IV) to the organometallic reagent is about 1:1 to about 1:2. In one embodiment, the molar ratio of the compound of Formula (IV) to the organometallic reagent is about 1:1.6.

[0122] In some embodiments, the compound of formula (IV) is converted to an organometallic reagent in step 3.0. In some embodiments, the organometallic reagent is formed in situ or isolated therefrom. In some embodiments, the compound of formula (IV) is converted to an organolithium, organomagnesium, or organozinc reagent. In some embodiments, the compound of formula (IV) is converted to an organomagnesium reagent. In some embodiments, the organomagnesium reagent is formed by contacting the compound of formula (IV) with a species of magnesium metal and optionally a catalyst. In another embodiment, the organomagnesium reagent is formed by contacting the compound of formula (IV) with iPrMgCl·LiCl.

[0123] Step 3.0 may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is tetrahydrofuran (THF), methyl tert-butyl ether (MTBE) or dimethylformamide (DMF) or a mixture thereof. In another embodiment, the solvent is tetrahydrofuran.

[0124] In some embodiments, step 3.0 is carried out at a reaction temperature of about -30 to about 10° C. In one embodiment, the reaction temperature is about -20° C.

[0125] In some embodiments, the compound of formula (III) formed in step 3.0 is converted to a salt of the compound. In one embodiment, the salt is a hydrochloride salt. In one embodiment, the salt is a bis-hydrochloride salt. In some embodiments, the salt is formed by reacting the compound of formula (III) with hydrochloric acid. In one embodiment, the compound of formula (III) is reacted with hydrochloric acid in a solvent of a mixture of methyltetrahydrofuran, isopropyl alcohol (IPA) and water.

[0126] In some embodiments, the method comprises: (Step 3.a) Reacting the compound of formula (III) prepared in Step 3.0, or a salt, solvate, hydrate or isotope thereof, with NaSO to obtain a compound of the formula: [ka] or a salt, solvate, hydrate or isotopologue thereof; (Step 3.b) converting the sodium sulfonate compound to a compound of formula (III) or a salt, solvate, hydrate or isotope thereof. Further includes:

[0127] In some embodiments, the free base form of the compound of formula (III) is isolated from step 3.0 and then reacted with Na2S2O5 in step 3.a. In some embodiments, Na2S2O5 is added as a solution in a protic solvent. In one embodiment, Na2S2O5 is added as a solution in ethanol or water or a combination thereof. In other embodiments, Na2S2O5 is added as a solid.

[0128] In some embodiments, step 3.b is carried out in the presence of a base. In some embodiments, step 3.b is carried out in the presence of an alkali metal base. In some embodiments, the base is an alkali metal hydroxide, carbonate, bicarbonate, phosphate, hydrogen phosphate, or dihydrogen phosphate. In some embodiments, the base is LiOH, NaOH, KOH, Na2CO3, K2CO3, Cs2CO3, NaHCO3, KHCO3, Na3PO4, K3PO4, Na2HPO4, K2HPO4, NaH2PO4, or KH2PO4. In one embodiment, the base is sodium carbonate (Na2CO3).

[0129] Step 3.b may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is a mixture of ethyl acetate (EtOAc) or water or a mixture thereof.

[0130] In some embodiments, the compound of formula (III) formed in step 3.b is converted to a salt of the compound. In one embodiment, the salt is an oxalate salt. In one embodiment, the salt is a bis-oxalate salt. In some embodiments, the salt is formed by reacting the compound of formula (III) with oxalic acid. In one embodiment, the compound of formula (III) is reacted with oxalic acid in a solvent of isopropyl alcohol (IPA) or water or a mixture thereof.

[0131] In one embodiment, the compound of formula (IV) is reacted with dimethylformamide in the presence of iPrMgCl·LiCl in a solvent of tetrahydrofuran; the free base form of the compound of formula (III) is isolated; a solution of Na2S2O5 in ethanol and water is then added; and the sodium sulfonate compound is then reacted with sodium carbonate in a solvent of a mixture of ethyl acetate and water. In one embodiment, the compound of formula (III) is converted to the bis-oxalate salt by treating the compound of formula (III) with oxalic acid in a solvent of a mixture of isopropyl alcohol (IPA) and water.

[0132] In some embodiments, provided herein is a process for the preparation of a compound of formula (IV), or a salt, solvate, hydrate, or isotopologue thereof, comprising: (Step 4.0) Reacting 4-(azetidin-3-yl)morpholine or a salt thereof with 4-bromo-3-fluorobenzaldehyde A method is provided that includes:

[0133] In some embodiments, a salt of 4-(azetidin-3-yl)morpholine is used in step 4.0. In one embodiment, the hydrochloride salt of 4-(azetidin-3-yl)morpholine is used. In one embodiment, the molar ratio of 4-bromo-3-fluorobenzaldehyde to 4-(azetidin-3-yl)morpholine hydrochloride is about 1:1.

[0134] In some embodiments, step 4.0 is performed in the presence of a reducing agent. In some embodiments, the reducing agent is a borohydride reagent. In some embodiments, the borohydride reagent is sodium borohydride, sodium tri(acetoxy)borohydride, or sodium cyanoborohydride. In one embodiment, the borohydride reagent is sodium tri(acetoxy)borohydride. In one embodiment, the molar ratio of 4-bromo-3-fluorobenzaldehyde to sodium tri(acetoxy)borohydride is about 1:1.7.

[0135] In some embodiments, step 4.0 is performed in the presence of a catalyst. In some embodiments, step 4.0 is performed in the presence of an acid catalyst. In some embodiments, step 4.0 is performed in the presence of a Lewis acid catalyst. In some embodiments, the Lewis acid catalyst is titanium tetra(isopropoxide) or zinc dichloride. In other embodiments, step 4.0 is performed in the presence of a Bronsted acid catalyst. In some embodiments, the Bronsted acid catalyst is an organic acid. In some embodiments, the Bronsted acid catalyst is formic acid, acetic acid, trifluoroacetic acid, or benzoic acid. In one embodiment, the hydrochloride salt of 4-(azetidin-3-yl)morpholine is the acid source.

[0136] Step 4.0 may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is acetonitrile.

[0137] In some embodiments, the compound of formula (IV) formed in step 4.0 is converted to a salt of the compound. In one embodiment, the salt is a citrate salt. In one embodiment, the salt is citric acid and is a bis-citrate salt. In one embodiment, the salt is a methanesulfonate salt. In one embodiment, the methanesulfonate salt is a bis-methanesulfonate salt. In one embodiment, the citrate salt of the compound of formula (IV) is converted to a methanesulfonate salt of the compound of formula (IV) in step 4.0.

[0138] In some embodiments, in step 4.0, the citrate salt of the compound of formula (IV) is formed by reacting the compound of formula (IV) with citric acid. In one embodiment, the compound of formula (IV) is reacted with citric acid in a solvent of cyclopentyl methyl ether.

[0139] In some embodiments, in step 4.0, the methanesulfonic acid salt of the compound of formula (IV) is formed by treating the citrate salt of the compound of formula (IV) with an aqueous base solution, followed by acidification with methanesulfonic acid. In some embodiments, the citrate salt of the compound of formula (IV) is treated with an aqueous solution of sodium hydroxide, optionally in the presence of a solvent of cyclopentyl methyl ether. In some embodiments, the acidification with methanesulfonic acid is carried out in the presence of a solvent of methanol or cyclopentyl methyl ether, or a mixture thereof.

[0140] In one embodiment, 4-bromo-3-fluorobenzaldehyde is reacted with the hydrochloride salt of 4-(azetidin-3-yl)morpholine and sodium tri(acetoxy)borohydride; and the compound of formula (IV) is optionally first converted to a citrate salt of the compound, and then the citrate salt is converted to a methanesulfonate salt of the compound.

[0141] In some embodiments, provided herein is a process for the preparation of a compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 5.0) Formula (VI): [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof. A method is provided that includes:

[0142] In some embodiments, step 5.0 is carried out under hydrogenation conditions. In one embodiment, hydrogenation is carried out in the presence of hydrogen gas. In other embodiments, hydrogenation is carried out under transfer hydrogenation conditions. In some embodiments, the transfer hydrogenation conditions include cyclohexene, cyclohexadiene, formic acid, or ammonium formate.

[0143] In some embodiments, step 5.0 is carried out in the presence of a palladium, platinum, rhodium or ruthenium catalyst on a variety of supports including carbon, alumina, alkaline earth carbonates, clays, ceramics or celite. In some embodiments, the hydrogenation is carried out in the presence of a palladium catalyst. In one embodiment, the catalyst is palladium on carbon (Pd / C).

[0144] Step 5.0 may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is isopropyl alcohol (IPA).

[0145] In one exemplary embodiment, the compound of formula (VI) is reacted with hydrogen gas in the presence of palladium on carbon as a catalyst.

[0146] In some embodiments, provided herein is a process for the preparation of a compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 6.0) Formula: [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof with 3-nitrophthalic anhydride. A method is provided that includes:

[0147] In some embodiments, a salt of (S)-tert-butyl 4,5-diamino-5-oxopentanoate is used in step 6.0. In one embodiment, the hydrochloride salt of (S)-tert-butyl 4,5-diamino-5-oxopentanoate is used.

[0148] In some embodiments, step 6.0 is performed in the presence of a base. In some embodiments, the base is a nitrogen-containing base. In some embodiments, the base is NH4OH, triethylamine, diisopropylethylamine (DIEA), pyridine, lutidine, 4-dimethylaminopyridine, imidazole, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). In one embodiment, the base is lutidine. In one embodiment, the lutidine is 2,3-lutidine, 2,4-lutidine, 2,5-lutidine, 2,6-lutidine, 3,4-lutidine, or 3,5-lutidine, or a mixture thereof.

[0149] In some embodiments, step 6.0 is performed in the presence of an activating reagent. In one embodiment, the activating reagent is 1,1'-carbonyldiimidazole (CDI).

[0150] Step 6.0 may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is a mixture of dimethylformamide (DMF), ethyl acetate (EtOAc) and methyltetrahydrofuran.

[0151] In one embodiment, the hydrochloride salt of (S)-tert-butyl 4,5-diamino-5-oxopentanoate is reacted with 3-nitrophthalic anhydride in the presence of lutidine as a base and 1,1′-carbonyldiimidazole as an activating reagent.

[0152] In some embodiments, provided herein is a process for the preparation of a compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 6.a) Formula: [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, having the formula: [ka] with ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate. A method is provided that includes:

[0153] In some embodiments, in step 6.a, a salt of (S)-tert-butyl 4,5-diamino-5-oxopentanoate is used. In one embodiment, the hydrochloride salt of (S)-tert-butyl 4,5-diamino-5-oxopentanoate is used.

[0154] In some embodiments, the molar ratio of (S)-tert-butyl 4,5-diamino-5-oxopentanoate to ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate is about 1:2 to 2:1. In one embodiment, the molar ratio of (S)-tert-butyl 4,5-diamino-5-oxopentanoate to ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate is about 1:1.

[0155] In some embodiments, step 6.a is performed in the presence of a base. In some embodiments, the base is a nitrogen-containing base. In some embodiments, the base is NH4OH, triethylamine, diisopropylethylamine (DIEA), pyridine, lutidine, 4-dimethylaminopyridine, imidazole, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). In one embodiment, the base is diisopropylethylamine (DIEA).

[0156] In some embodiments, the molar ratio of (S)-tert-butyl 4,5-diamino-5-oxopentanoate to the base is about 1:1 to 1:2. In one embodiment, the molar ratio of (S)-tert-butyl 4,5-diamino-5-oxopentanoate to the base is about 1:1.4.

[0157] Step 6.a may be carried out in a suitable solvent for the reaction. In one embodiment, the solvent is tetrahydrofuran.

[0158] In some embodiments, step 6.a is carried out at a reaction temperature of about 60° C. to about 80° C. In one embodiment, the reaction temperature is about 68° C.

[0159] In some embodiments, step 6.a is carried out for a reaction time of about 6 hours to about 18 hours, hi one embodiment, the reaction time is about 10 hours.

[0160] In one exemplary embodiment, (S)-tert-butyl 4,5-diamino-5-oxopentanoate is reacted with ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate in the presence of diisopropylethylamine as a base, the molar ratio of (S)-tert-butyl 4,5-diamino-5-oxopentanoate to ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate is about 1:1, the molar ratio of (S)-tert-butyl 4,5-diamino-5-oxopentanoate to diisopropylethylamine is about 1:1.4, and the solvent is tetrahydrofuran. In one embodiment, the reaction temperature is about 68° C., and the reaction time is about 10 hours. In one embodiment, the compound of formula (VI) is purified by precipitation with methyl tert-butyl ether, extraction into dichloromethane, and trituration with a mixture of hexane and ethyl acetate.

[0161] In some embodiments, provided herein is a method for the preparation of ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate, comprising: (Step 6.b) Reacting 4-nitroisoindoline-1,3-dione with ethyl chloroformate A method is provided that includes:

[0162] In some embodiments, the molar ratio of 4-nitroisoindoline-1,3-dione to ethyl chloroformate is about 2:1 to about 1:2. In one embodiment, the molar ratio of 4-nitroisoindoline-1,3-dione to ethyl chloroformate is about 1:1.25.

[0163] In some embodiments, step 6.b is performed in the presence of a base. In some embodiments, the base is a nitrogen-containing base. In some embodiments, the base is NH4OH, triethylamine, diisopropylethylamine (DIEA), pyridine, lutidine, 4-dimethylaminopyridine, imidazole, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). In one embodiment, the base is trimethylamine (TEA).

[0164] In some embodiments, the molar ratio of 4-nitroisoindoline-1,3-dione to base is about 1:1 to about 1:2. In one embodiment, the molar ratio of 4-nitroisoindoline-1,3-dione to base is about 1:1.13.

[0165] Step 6.b may be carried out in a solvent suitable for the reaction. In one embodiment, the solvent is dimethylformamide. In one embodiment, the dimethylformamide is anhydrous.

[0166] In some embodiments, step 6.b is carried out at a reaction temperature of about 0° C. to about 30° C. In one embodiment, the reaction temperature is about 22° C.

[0167] In some embodiments, step 6.b is carried out for a reaction time of about 6 hours to about 18 hours, hi one embodiment, the reaction time is about 10 hours.

[0168] In one embodiment, 4-nitroisoindoline-1,3-dione is reacted with ethyl chloroformate in the presence of diisopropylethylamine as a base, the molar ratio of 4-nitroisoindoline-1,3-dione to ethyl chloroformate is about 1:1.25, the molar ratio of 4-nitroisoindoline-1,3-dione to diisopropylethylamine is about 1:1.13, and the solvent is dimethylformamide. In one embodiment, the reaction temperature is about 22° C. and the reaction time is about 10 hours. In one embodiment, 4-nitro-1,3-dioxoisoindoline-2-carboxylate is optionally purified by filtration followed by selective extraction into ethyl acetate.

[0169] In certain embodiments, the methods provided herein result in improved chiral purity of one or more intermediates and / or products throughout the pathway.

[0170] In certain embodiments, the methods provided herein result in improved impurity profiles of one or more intermediates and / or products throughout the pathway.

[0171] In certain embodiments, the methods provided herein result in a more convergent synthesis of one or more intermediates and / or products throughout the pathway.

[0172] All combinations of the above embodiments are encompassed by the present invention.

[0173] In one embodiment, provided herein is a process for the preparation of a compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, comprising: (Step 1.0) cyclizing a compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, to provide a compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof; (Step 1.1) Optionally, converting a compound of formula (I) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof into a salt of the compound; wherein the compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is (Step 2.0) reacting a compound of formula (III), or a salt, solvate, hydrate, or isotopologue thereof, with a compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof and the compound of formula (III), or a salt, solvate, hydrate or isotope thereof, is prepared by a process comprising: (Step 3.0) reacting a compound of formula (IV), or a salt, solvate, hydrate or isotope thereof, with a formaldehyde source. The compound of formula (IV), or a salt, solvate, hydrate or isotope thereof, is prepared by a process comprising: (Step 4.0) Reacting 4-(azetidin-3-yl)morpholine or a salt thereof with 4-bromo-3-fluorobenzaldehyde and the compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 5.0) Reducing a compound of formula (VI) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof and the compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 6.0) Reacting (S)-tert-butyl 4,5-diamino-5-oxopentanoate or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof with 3-nitrophthalic anhydride It is prepared by a method comprising:

[0174] In another embodiment, the present specification provides (Step 1.0) cyclizing a compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, to provide a compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof; (Step 1.1) Optionally, converting a compound of formula (I) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof into a salt of the compound; and a compound of formula (II) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof is provided by a process comprising: (Step 2.0) reacting a compound of formula (III), or a salt, solvate, hydrate, or isotopologue thereof, with a compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof and the compound of formula (III), or a salt, solvate, hydrate or isotope thereof, is prepared by a process comprising: (Step 3.0) reacting a compound of formula (IV), or a salt, solvate, hydrate or isotope thereof, with a formaldehyde source; (Step 3.a) reacting the compound of formula (III) prepared in Step 3.0, or a salt, solvate, hydrate or isotopologue thereof, with NaSO to provide a sodium sulfonate compound, or a salt, solvate, hydrate or isotopologue thereof; (Step 3.b) converting the sodium sulfonate compound to a compound of formula (IV) or a salt, solvate, hydrate or isotope thereof. and the compound of formula (IV), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 4.0) Reacting 4-(azetidin-3-yl)morpholine or a salt thereof with 4-bromo-3-fluorobenzaldehyde and the compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 5.0) Reducing a compound of formula (VI) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof and the compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 6.0) Reacting (S)-tert-butyl 4,5-diamino-5-oxopentanoate or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof with 3-nitrophthalic anhydride It is prepared by a method comprising:

[0175] In another embodiment, the present specification provides (Step 1.0) cyclizing a compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, to provide a compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof; (Step 1.1) Optionally, converting a compound of formula (I) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof into a salt of the compound; and a compound of formula (II) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof is provided by a process comprising: (Step 2.a) reacting a compound of formula (II-A), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, with 4-(azetidin-3-yl)morpholine, or a salt thereof. and the compound of formula (II-A), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 2.b) chlorinating a compound of formula (II-B) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof. and the compound of formula (II-B), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotope thereof, is prepared by a process comprising: (Step 2.c) reacting a compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, with 2-fluoro-4-(hydroxymethyl)benzaldehyde. and the compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 5.0) Reducing a compound of formula (VI) or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof and the compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is prepared by a process comprising: (Step 6.a) reacting (S)-tert-butyl 4,5-diamino-5-oxopentanoate or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof with ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate. and ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate is prepared by a method comprising: (Step 6.b) Reacting 4-nitroisoindoline-1,3-dione with ethyl chloroformate It is prepared by a method comprising:

[0176] 6.3 Compounds and solid forms In one embodiment, provided herein is an intermediate compound used in a method provided herein or a product compound prepared by a method provided herein, including a solid form thereof (e.g., a crystalline form).

[0177] In one embodiment, the present specification provides Compound 1: [ka] A bisbesylate salt of the formula is provided.

[0178] In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1 (e.g., Form B). Certain salts and solid forms of Compound 1, including Form A of the hydrochloride salt of Compound 1 and Form A of the besylate salt of Compound 1, are described in U.S. Patent Publication No. 2021-0115019, the entirety of which is incorporated herein by reference.

[0179] In one embodiment, the present disclosure provides compound 2: [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof is provided.

[0180] In one embodiment, the present specification provides compound 2-a: [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof is provided.

[0181] In one embodiment, the present disclosure provides compound 2-b: [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof is provided.

[0182] In one embodiment, the present specification provides compound 3: [ka] or a salt, solvate, hydrate or isotope thereof is provided.

[0183] In one embodiment, provided herein is a salt of Compound 3. In one embodiment, the salt is a hydrochloride salt. In one embodiment, the hydrochloride salt is a dihydrochloride salt. In one embodiment, provided herein is a solid form (e.g., Form A or Form B) comprising the hydrochloride salt of Compound 3. In one embodiment, the salt is an oxalate salt. In one embodiment, the oxalate salt is a bis-oxalate salt.

[0184] In one embodiment, the present specification provides compound 4: [ka] or a salt, solvate, hydrate or isotope thereof is provided.

[0185] In one embodiment, provided herein is a salt of Compound 4. In one embodiment, the salt is a methanesulfonate salt. In one embodiment, the methanesulfonate salt is a bismethanesulfonate salt. In one embodiment, provided herein is a solid form comprising a methanesulfonate salt of Compound 4 (e.g., Form A).

[0186] In one embodiment, the present specification provides compound 5: [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof is provided.

[0187] In one embodiment, the present specification provides compound 6: [ka] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof is provided.

[0188] 5.3.1 Besylate Form B of Compound 1 In one embodiment, the present specification provides Compound 1: [ka] wherein the solid form is Form B (of the besylate salt of Compound 1).

[0189] In some embodiments, the molar ratio of Compound 1 to benzenesulfonic acid in the solid form ranges from about 1:1 to about 1:2. In one embodiment, the molar ratio is about 1:2 (i.e., the bisbesylate salt).

[0190] In one embodiment, Form B is crystalline. In one embodiment, Form B is substantially crystalline. In one embodiment, Form B is moderately crystalline. In one embodiment, Form B is partially crystalline.

[0191] A representative XRPD pattern of Form B of the besylate salt of Compound 1 is provided in FIG.

[0192] In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1 characterized by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or all of the XRPD peaks located at approximately the following positions: 4.7, 6.7, 7.5, 9.4, 10.2, 11.3, 12.1, 13.4, 14.3, 16.0, 17.2, 18.6, 19.9, 21.4, 22.4, 23.5, 24.6, and 26.9 °2θ. In one embodiment, the solid form is characterized by three of the peaks. In one embodiment, the solid form is characterized by five of the peaks. In one embodiment, the solid form is characterized by seven of the peaks. In one embodiment, the solid form is characterized by nine of the peaks. In one embodiment, the solid form is characterized by eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0193] In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1, characterized by an XRPD pattern comprising peaks at about 6.7, 7.5, and 17.2 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 16.0 and 23.5 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 9.4 and 11.3 °2θ. In one embodiment, the XRPD pattern comprises peaks at about 6.7, 7.5, 9.4, 11.3, 16.0, 17.2, 22.4, 23.5, and 26.9 °2θ.

[0194] In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1, characterized by an XRPD pattern that matches the XRPD pattern provided in FIG.

[0195] In one embodiment, the XRPD pattern is obtained using Cu Kα radiation.

[0196] Representative thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) thermograms of Form B are provided in Figures 2 and 3, respectively. In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1, which exhibits a weight loss of about 2.1% when heated from about 25°C to about 125°C. In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1, which exhibits a weight loss of about 2.7% when heated from about 25°C to about 200°C. In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1, which is characterized by a TGA thermogram consistent with the TGA thermogram provided in Figure 2.

[0197] In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1, which exhibits a thermal event (endotherm) as characterized by DSC with an onset temperature of about 164° C. In one embodiment, the thermal event also has a peak temperature of about 175° C. In one embodiment, provided herein is a solid form comprising a besylate salt of Compound 1, which is characterized by a DSC thermogram consistent with the DSC thermogram depicted in FIG.

[0198] In one embodiment, Form B of the besylate salt of Compound 1 is prepared by (i) adding an anti-solvent to a mixture of the besylate salt of Compound 1 in acetonitrile to form a slurry, and (ii) slurried the slurry to provide Form B of the besylate salt of Compound 1. In one embodiment, the anti-solvent is MeTHF. In one embodiment, the anti-solvent is MTBE. In one embodiment, the mixture of the besylate salt of Compound 1 in acetonitrile is formed by adding benzenesulfonic acid to a solution of the free base of Compound 1 in acetonitrile (e.g., at about 55° C.). In one embodiment, the solution of the free base of Compound 1 in acetonitrile also contains water. In one embodiment of (ii), the slurry is slurried at about 20° C. for a period of time (e.g., from about 1 hour to about 24 hours, e.g., about 6 hours or overnight).

[0199] In one embodiment, provided herein is a solid form comprising Form B of the besylate salt of Compound 1 and one or more forms (e.g., amorphous and crystalline forms) of the free base of Compound 1. In one embodiment, provided herein is a solid form comprising Form B of the besylate salt of Compound 1 and an amorphous besylate salt of Compound 1. In one embodiment, provided herein is a solid form comprising Form B of the besylate salt of Compound 1 and one or more other crystalline forms of the besylate salt of Compound 1. In one embodiment, provided herein is a solid form comprising Form B of the besylate salt of Compound 1 and one or more forms (e.g., amorphous or crystalline) of the salts of Compound 1 provided herein.

[0200] 5.3.2 Form A of the hydrochloride salt of compound 3 In one embodiment, the present specification provides compound 3: [ka] wherein the solid form is Form A (of the compound Compound 3).

[0201] In some embodiments, the molar ratio of compound 3 to hydrochloric acid in the solid form ranges from about 1:1 to about 1:2. In one embodiment, the molar ratio is about 1:2 (i.e., the dihydrochloride salt).

[0202] In one embodiment, Form A is crystalline. In one embodiment, Form A is substantially crystalline. In one embodiment, Form A is moderately crystalline. In one embodiment, Form A is partially crystalline.

[0203] In one embodiment, Form A is the anhydrous form of the hydrochloride salt of Compound 3 (anhydrous).

[0204] A representative XRPD pattern of Form A of the hydrochloride salt of Compound 3 is provided in Figure 5. In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, 20, 21, twenty, 23, twenty-four or all of the XRPD peaks located at about the following positions: 8.8, 10.9, 14.3, 14.6, 14.9, 15.8, 17.3, 17.6, 18.4, 19.4, 19.8, 20.5, 21.8, 22.8, 23.5, 24.2, 24.7, 25.2, 26.0, 26.4, 26.8, 27.7, 28.0, 28.4, and 28.8 °2θ. In one embodiment, the solid form is characterized by three of the peaks. In one embodiment, the solid form is characterized by five of the peaks. In one embodiment, the solid form is characterized by seven of the peaks. In one embodiment, the solid form is characterized by nine of the peaks. In one embodiment, the solid form is characterized by eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0205] In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, characterized by an XRPD pattern comprising peaks at about 14.6, 19.4, and 21.8 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 15.8 and 22.8 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 8.8, 14.3, and 14.9 °2θ. In one embodiment, the XRPD pattern comprises peaks at about 8.8, 14.3, 14.6, 14.9, 15.8, 17.6, 18.4, 19.4, 21.8, and 22.8 °2θ.

[0206] In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, characterized by an XRPD pattern that matches the XRPD pattern provided in FIG.

[0207] In one embodiment, the XRPD pattern is obtained using Cu Kα radiation.

[0208] A representative differential scanning calorimetry (DSC) thermogram of Form A is provided in Figure 6. In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, which exhibits a thermal event (endotherm) with an onset temperature of about 178°C, as characterized by DSC. In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, which is characterized by a DSC thermogram consistent with the DSC thermogram shown in Figure 6.

[0209] In one embodiment, provided herein is a solid form comprising Form A of the hydrochloride salt of Compound 3 and one or more forms of the free base of Compound 3 (e.g., amorphous and crystalline forms). In one embodiment, provided herein is a solid form comprising Form A of the hydrochloride salt of Compound 3 and an amorphous hydrochloride salt of Compound 3. In one embodiment, provided herein is a solid form comprising Form A of the hydrochloride salt of Compound 3 and one or more other crystalline forms of the hydrochloride salt of Compound 3. In one embodiment, provided herein is a solid form comprising Form A of the hydrochloride salt of Compound 3 and one or more forms (e.g., amorphous or crystalline) of the salts of Compound 3 provided herein.

[0210] 5.3.3 Form B of the hydrochloride salt of compound 3 In one embodiment, the present specification provides compound 3: [ka] wherein the solid form is Form B (of the compound Compound 3).

[0211] In some embodiments, the molar ratio of compound 3 to hydrochloric acid in the solid form ranges from about 1:1 to about 1:2. In one embodiment, the molar ratio is about 1:2 (i.e., the dihydrochloride salt).

[0212] In one embodiment, Form B is crystalline. In one embodiment, Form B is substantially crystalline. In one embodiment, Form B is moderately crystalline. In one embodiment, Form B is partially crystalline.

[0213] In one embodiment, Form B is a solvate of the hydrochloride salt of Compound 3. In one embodiment, Form B is a hydrate of the hydrochloride salt of Compound 3.

[0214] A representative XRPD pattern of Form B of the hydrochloride salt of Compound 3 is provided in FIG. In an embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, twelfth, eleventh, twelve, thirteen, fourteenth, fifteenth, six, seven, eight, nine, twelfth, nine, twelfth, twenty, one, two, three, three, four, four, five ... In one embodiment, the solid form is characterized by three of the peaks. In one embodiment, the solid form is characterized by five of the peaks. In one embodiment, the solid form is characterized by seven of the peaks. In one embodiment, the solid form is characterized by nine of the peaks. In one embodiment, the solid form is characterized by eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0215] In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, characterized by an XRPD pattern comprising peaks at about 14.3, 15.4, and 16.2 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 14.8, 17.8, and 19.4 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 7.8 and 21.0 °2θ. In one embodiment, the XRPD pattern comprises peaks at about 7.8, 11.8, 14.3, 14.8, 15.4, 16.2, 17.8, 19.4, 20.5, and 21.0 °2θ.

[0216] In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, characterized by an XRPD pattern that matches the XRPD pattern provided in FIG.

[0217] In one embodiment, the XRPD pattern is obtained using Cu Kα radiation.

[0218] Representative thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) thermograms of Form B are provided in Figures 8 and 9, respectively. In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, which exhibits a weight loss of about 5.2% when heated from about 25°C to about 125°C. In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, characterized by a TGA thermogram consistent with the TGA thermogram provided in Figure 8.

[0219] In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, which exhibits a thermal event (endotherm) as characterized by DSC with an onset temperature of about 130° C. In one embodiment, provided herein is a solid form comprising the hydrochloride salt of Compound 3, which is characterized by a DSC thermogram consistent with the DSC thermogram shown in FIG.

[0220] In one embodiment, provided herein is a solid form comprising Form B of the hydrochloride salt of Compound 3 and one or more forms of the free base of Compound 3 (e.g., amorphous and crystalline forms). In one embodiment, provided herein is a solid form comprising Form B of the hydrochloride salt of Compound 3 and an amorphous hydrochloride salt of Compound 3. In one embodiment, provided herein is a solid form comprising Form B of the hydrochloride salt of Compound 3 and one or more other crystalline forms of the hydrochloride salt of Compound 3. In one embodiment, provided herein is a solid form comprising Form B of the hydrochloride salt of Compound 3 and one or more forms (e.g., amorphous or crystalline) of the salts of Compound 3 provided herein.

[0221] 5.3.4 Form A of the methanesulfonate salt of compound 4 In one embodiment, the present specification provides compound 4: [ka] wherein the solid form is Form A (of the methanesulfonate salt of Compound 4).

[0222] In some embodiments, the molar ratio of compound 4 to methanesulfonic acid in the solid form ranges from about 1:1 to about 1:2. In one embodiment, the molar ratio is about 1:2 (i.e., the bismethanesulfonate salt).

[0223] In one embodiment, Form A is crystalline. In one embodiment, Form A is substantially crystalline. In one embodiment, Form A is moderately crystalline. In one embodiment, Form A is partially crystalline.

[0224] A representative XRPD pattern of Form A of the methanesulfonate salt of compound 4 is provided in FIG. In an embodiment, provided herein is a solid form comprising a methanesulfonate salt of Compound 4, characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, twelfth, or all of the XRPD peaks located at about the following positions: 8.0, 9.3, 10.4, 12.2, 13.1, 13.9, 16.0, 16.7, 18.0, 18.6, 20.3, 20.8, 21.3, 22.2, 22.7, 22.9, 23.2, 24.1, 24.6, 25.1, 25.9, 26.3, 27.9, 28.4, 29.1, and 29.5 °2θ. In one embodiment, the solid form is characterized by three of the peaks. In one embodiment, the solid form is characterized by five of the peaks. In one embodiment, the solid form is characterized by seven of the peaks. In one embodiment, the solid form is characterized by nine of the peaks. In one embodiment, the solid form is characterized by eleven of the peaks. In one embodiment, the solid form is characterized by all of the peaks.

[0225] In one embodiment, provided herein is a solid form comprising a methanesulfonate salt of compound 4, characterized by an XRPD pattern comprising peaks at about 18.6, 20.3, and 20.8 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 16.7 and 22.7 °2θ. In one embodiment, the XRPD pattern further comprises peaks at about 8.0 and 24.6 °2θ. In one embodiment, the XRPD pattern comprises peaks at about 8.0, 10.4, 13.1, 13.9, 16.0, 16.7, 18.6, 20.3, 20.8, 22.7, and 24.6 °2θ.

[0226] In one embodiment, provided herein is a solid form comprising a methanesulfonate salt of compound 4, characterized by an XRPD pattern that matches the XRPD pattern provided in FIG.

[0227] In one embodiment, the XRPD pattern is obtained using Cu Kα radiation.

[0228] A representative differential scanning calorimetry (DSC) thermogram of Form A of the methanesulfonate salt of Compound 4 is provided in Figure 11. In one embodiment, provided herein is a solid form comprising the methanesulfonate salt of Compound 4, which exhibits a thermal event (endotherm) as characterized by DSC with an onset temperature of about 213°C. In one embodiment, the thermal event also has a peak temperature of about 216°C. In one embodiment, provided herein is a solid form comprising the methanesulfonate salt of Compound 4, which is characterized by a DSC thermogram consistent with the DSC thermogram shown in Figure 11.

[0229] In one embodiment, Form A of the methanesulfonate salt of Compound 4 is prepared by adding methanesulfonic acid to a mixture of Compound 4 in CPME (e.g., at about 50 to about 60° C.) to form a slurry, and (ii) slurriing the slurry to provide Form A of the methanesulfonate salt of Compound 4. In one embodiment of (ii), the slurry is slurried at about 20° C. for a period of time (e.g., about 1 hour to about 24 hours, e.g., about 3 to about 4 hours).

[0230] In one embodiment, provided herein is a solid form comprising Form A of the methanesulfonate salt of Compound 4 and one or more forms of the free base of Compound 4 (e.g., amorphous and crystalline forms). In one embodiment, provided herein is a solid form comprising Form A of the methanesulfonate salt of Compound 4 and an amorphous methanesulfonate salt of Compound 4. In one embodiment, provided herein is a solid form comprising Form A of the methanesulfonate salt of Compound 4 and one or more other crystalline forms of the methanesulfonate salt of Compound 4. In one embodiment, provided herein is a solid form comprising Form A of the methanesulfonate salt of Compound 4 and one or more forms of the salt of Compound 4 provided herein (e.g., amorphous or crystalline).

[0231] All combinations of the above embodiments are encompassed by the present invention. EXAMPLES

[0232] As used herein, the symbols and conventions used in these methods, schemes and examples are consistent with those used in modern scientific literature, such as the Journal of the American Chemical Society or the Journal of Biological Chemistry, regardless of whether a particular abbreviation is specifically defined.Specifically, but not limited to, the following abbreviations may be used in the examples and throughout this specification: g (gram); mg (milligram); mL (milliliter); μL (microliter); M (molar concentration); mM (millimolar concentration); μM (micromolar concentration); eq. (equivalent); mmol (millimolar); Hz (Hertz); MHz (Megahertz); hr or hrs (hours); min (minutes); and MS (mass spectrometry).Unless otherwise specified, the water content in the compounds provided herein is determined by the Karl Fischer (KF) method.

[0233] For all of the following examples, unless otherwise specified, standard work-up and purification methods known to those skilled in the art can be utilized. Unless otherwise specified, all temperatures are expressed in °C (degrees Celsius). All reactions were carried out at room temperature unless otherwise noted. The synthetic methodology presented herein is intended to illustrate applicable chemistry through the use of specific examples and is not indicative of the scope of the present disclosure.

[0234] Example 1: Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione [ka] Synthesis of ethyl 4-nitro-1,3-dioxo-isoindoline-2-carboxylate (compound 10): A solution of 4-nitroisoindoline-1,3-dione (compound 11, 440 g, 2.29 mol) and TEA (262 g, 2.59 mol, 359 mL) in dry DMF (2.2 L) was cooled to 0° C. and ethyl chloroformate (313 g, 2.89 mol, 275 mL) was added dropwise over 5 min. The reaction mixture was stirred at 22° C. for 10 h. The mixture was slowly added to cold water (10 L) and the resulting suspension was stirred for 5 min. The suspension was filtered and the filter cake was washed with water (1 L). The solid was dissolved with ethyl acetate (5 L) and the organic phase was washed with aqueous HCl (1 M, 1 L), water (2 L) and brine (2 L). The organic phase was dried over sodium sulfate, filtered and concentrated to give compound 10 (360 g, 59%) as a white solid. 1 H NMR(400MHz CDCl3)δ ppm 8.24(d,J=7.6Hz,1H),8.19(d,J=8.4Hz,1H),8.06-8.02(m,1H),4.49(q,J=7.2Hz,2H),1.44(t,J=6.8Hz,3H).

[0235] Synthesis of tert-butyl (4S)-5-amino-4-(4-nitro-1,3-dioxo-isoindolin-2-yl)-5-oxo-pentanoate (compound 6): To a solution of compound 10 (165 g, 625 mmol) and DIEA (113 g, 874 mmol, 153 mL) in dry THF (1700 mL), tert-butyl (4S)-4,5-diamino-5-oxo-pentanoate hydrochloride (149 g, 625 mmol) was added and heated to reflux for 10 h. The reaction mixture was concentrated under reduced pressure. The resulting residue was diluted with methyl tert-butyl ether (5 L) and stirred at 20° C. for 1 h. The suspension was filtered and the filter cake was dissolved with DCM (4 L). The organic phase was washed with water (1.5 L×3), brine (1.5 L) and dried over sodium sulfate. The organic phase was filtered and concentrated under reduced pressure to give a pale yellow oil. The oil was diluted with hexane / ethyl acetate (10 / 1, 2 L) and stirred until a pale yellow suspension was formed. The suspension was filtered, the filter cake was triturated and concentrated in vacuo to give compound 6 (175 g, 74%) as a pale yellow solid. 1 H NMR(400MHz CDCl3)δ ppm 8.12(d,J=8.0Hz,2H),7.94(t,J=8.0Hz,1H),6.48(s,1H),5.99(s,1H),4.84-4.80(m,1H),2.49-2.44(m,2H),2.32-2.27(m,2H),1.38(s,9H).

[0236] Synthesis of tert-butyl (S)-5-amino-4-(4-amino-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 5): To a suspension of compound 6 (170.0 g, 450.5 mmol, 1.00 eq) in DMA (1.00 L) was added palladium on carbon (50.0 g, 10% purity) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen gas several times. The mixture was stirred at 25° C. for 16 h under hydrogen gas (50 psi). The mixture was filtered and the filtrate was poured into cold water (3.0 L). The mixture was stirred at 10° C. for 1 h and filtered. The filter cake was washed with water (700 mL) and dissolved in DCM (1.00 L). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to give compound 5 (107 g, 68%) as a green solid. 1 H NMR(400MHz DMSO-d6)δ ppm 7.52(s,1H),7.43(dd,J=8.4,7.2Hz,1H),7.13(s,1H),6.95-6.99(m,2H),6.42(s,2H),5.75(s,1H),4. 47-4.51 (m, 1H), 2.32-2.33 (m, 1H), 2.14-2.20 (m, 3H), 1.32 (s, 9H); HPLC purity, 100.0%; SFC purity, 100.0%ee.

[0237] Synthesis of 2-fluoro-4-(hydroxymethyl)benzaldehyde (compound 8): To a solution of 4-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzaldehyde (370.0 g, 1.38 mol, 1.00 eq) in THF (1.85 L) was added dropwise a solution of p-toluenesulfonic acid monohydrate (78.7 g, 413.6 mmol, 0.30 eq) in water (1.85 L) at 10° C. The mixture was stirred at 27° C. for 16 h. TEA (80 mL) was added dropwise and stirred for 10 min. The organic phase was separated and the aqueous phase was extracted with ethyl acetate (600 mL×4). The combined organic phase was washed with brine (1.50 L), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 8 (137.5 g, 76%) as a yellow oil. 1H NMR(400MHz CDCl3)δ ppm 10.34(s,1H),7.86(dd,J=8.0,7.2Hz,1H),7.25(s,1H),7.22(d,J=4.4Hz,1H),4.79(d,J=6.0Hz,2H),1.91(t,J=6.0Hz,1H).

[0238] Synthesis of tert-butyl (S)-5-amino-4-(4-((2-fluoro-4-(hydroxymethyl)benzyl)amino)-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 2-b): To a solution of compound 5 (100.0 g, 287.9 ​​mmol, 1.00 eq) and compound 8 (57.7 g, 374.3 mmol, 1.30 eq) in dry DCM (1.00 L) was added TFA (164.1 g, 1.44 mol, 5.00 eq) at 0° C. The reaction mixture was stirred at 28° C. for 2 hours. To this solution was added sodium cyanoborohydride (27.1 g, 431.8 mmol, 1.50 eq) at 0° C. The mixture was stirred at 28° C. for 30 minutes. The reaction mixture was quenched by the addition of MeOH (600 mL) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 2-b (110.0 g, 74.0%) as a yellow solid. 1 H NMR(400MHz,DMSO-d6)δ ppm 7.56(s,1H),7.50(dd,J=8.4,7.2Hz,1H),7.34(t,J=8.0Hz,1H),7.02-7.18(m,4H),6.94-7.01(m,2H),4.57(d,J=6 .0Hz,2H),4.47-4.53(m,3H),2.31-2.35(m,1H),2.15-2.22(m,3H),1.31(s,9H); HPLC purity, 94.0%; SFC purity, 100.0%ee.

[0239] Synthesis of tert-butyl (S)-5-amino-4-(4-((4-(chloromethyl)-2-fluorobenzyl)amino)-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 2-a): To a solution of compound 2-b (100.0 g, 206.0 mmol, 1.00 eq) in NMP (430.0 mL) was added DIEA (79.9 g, 617.9 mmol, 3.00 eq) and MsCl (47.2 g, 411.9 mmol, 2.00 eq) at 0° C. The ice bath was removed and the reaction was stirred at 28° C. for 10 h. The reaction was poured into cold water (<10° C., 2.0 L) and stirred for 10 min. The mixture was extracted with methyl tert-butyl ether (750 mL×3). The combined organic layers were washed with brine (1.25 L), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 2-a (86.0 g, 81.2%) as a yellow solid. 1 H NMR(400MHz DMSO-d6)δ ppm 7.55(s,1H),7.50(dd,J=8.4,7.2Hz,1H),7.38(t,J=8.0Hz,1H),7.31(dd,J=10.8,1.6 Hz,1H),7.23(dd,J=8.0,1.6Hz,1H),7.16(s,1H),7.11(t,J=6.4Hz,1H),7.00(d,J=7. 2Hz,1H),6.95(d,J=8.4Hz,1H),4.74(s,2H),4.61(d,J=6.4Hz,2H),4.49-4.53(m,1H) ,2.29-2.38(m,1H),2.16-2.25(m,3H),1.30(s,9H); HPLC purity, 98.0%; SFC purity, 100.0%ee.

[0240] Synthesis of tert-butyl (S)-5-amino-4-(4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 2): To a solution of 4-(azetidin-3-yl)morpholine hydrochloride (compound 7 HCl, 30.5 g, 170.7 mmol, 1.00 eq) and DIEA (66.2 g, 512.0 mmol, 3.00 eq) in DMSO (350.0 mL) was added dropwise a solution of compound 2-a (86 g, 170.65 mmol, 1.00 eq) in DMSO (350.0 mL) at 15° C. The reaction mixture was stirred at 28° C. for 16 h. The reaction mixture was poured into half-saturated cold brine (<10° C., 2.5 L) and extracted with ethyl acetate (1.50 L, 1.00 L, 800.0 mL). The combined organic phase was washed with saturated brine (1.50 L), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 2 (68.3 g, 65.7%) as a yellow solid. 1 H NMR(400MHz DMSO-d6)δ ppm 7.55(s,1H),7.50(dd,J=8.4,7.2Hz,1H),7.31(t,J=8.0Hz,1H),7.16(s,1H),6.94-7.10(m,5H),4.56(d,J=6.4Hz,2H),4.49-4.52(m,1H),3 .54-3.55(m,6H)3.31-3.32(m,3H),2.81-2.88(m,3H),2.29-2.38(m,1H),2.15-2.25(m,7H),1.30(s,9H);HPLC purity, 100.0%;SFC purity, 100.0%ee.

[0241] Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (compound 1): A solution of compound 2 (30.0 g, 49.2 mmol, 1.00 eq) and benzenesulfonic acid (31.1 g, 196.8 mmol, 4.00 eq) in acetonitrile (480.0 mL) was stirred at reflux for 3 h. The reaction was cooled to 20° C., poured into cold brine:saturated sodium bicarbonate solution (1:1, <10° C., 2.0 L) and extracted with ethyl acetate (1.0 L). The organic phase was washed once more with cold brine:saturated sodium bicarbonate solution (1:1, <10° C., 1.00 L). The combined aqueous phase was extracted with ethyl acetate (500.0 mL×2). The combined organic phase was washed with cold brine (<10° C., 1.0 L), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to give compound 1 (17.5 g, 66.0%) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ ppm 11.10(s,1H),7.54(t,J=8.0Hz,1H),7.30(t,J=8.0Hz,1H),7.04-7.10(m,4H),7 .00(d,J=8.4Hz,1H),5.07(dd,J=12.8,5.2Hz,1H),4.58(d,J=6.4Hz,2H),3.53- 3.55(m,6H),3.30-3.32(m,2H),2.81-2.89(m,4H),2.54-2.61(m,2H),2.20(m,4) H)2.03-2.06(m,1H);HPLC purity, 100.0%;SFC purity, 97.2%ee;LCMS(ESI)m / z536.1[M+H] + .

[0242] Example 2: Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione [ka] Synthesis of tert-butyl (S)-5-amino-4-(4-nitro-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 6): Ethyl acetate (245 mL, 5 V), 3-nitrophthalic anhydride (49.1 g, 0.25 mol, 1 eq) and tert-butyl (S)-4,5-diamino-5-oxopentanoate hydrochloride (59.2 g, 0.25 mol, 1 eq) were charged to a reactor and cooled to 15-20 °C. A pre-made solution of CDI (66.7 g, 0.41 mol, 1.5 eq) in DMF (245 mL, 5 V) was charged and the mixture was stirred at 20-25 °C for 1 h. The reaction was quenched with 15% (wt / wt) aqueous citric acid (10 V). EtOAc (5 V) was added, the mixture was stirred, and the phases were partitioned and separated. The aqueous layer was extracted with EtOAc (5 V) and the combined organic layers were washed twice with 5% (wt / wt) aqueous citric acid (5 V for each wash). The organic layers were distilled under reduced pressure to 5 V, and iPrOH (10 V) was added while maintaining a constant volume of 5 V, followed by further continuous distillation under reduced pressure. The final distillate was diluted to 13 V with iPrOH and used in the next step without further manipulation. Solution yield 91%.

[0243] Synthesis of tert-butyl (S)-5-amino-4-(4-amino-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 5): A solution of compound 6 in iPrOH was charged to a hydrogenation reactor. 10% palladium on carbon (50% wet, 4.65 g 5 wt%) was charged. The reaction mixture was stirred at 40-50 °C for 16 h under 50-60 psi H2. The reaction mixture was filtered and the filter cake was washed three times with iPrOH (1 V wash each). The solution was vacuum distilled to 5 V, cooled to ambient temperature, and seeded (1 wt%). Water (20 V) was charged at 20-25 °C. The resulting slurry was cooled to 3-8 °C for 4-8 h. The solid was collected by filtration and washed three times with cold water (1.5 V wash each). The solid was dried under reduced pressure at 35-45°C to obtain compound 5 in 87% yield. 1H NMR(500MHz DMSO-d6)δ(ppm):7.52(s,1H),7.43(dd,J=8.4,7.0Hz,1H),7.13(s,1H),6.97(ddd,J=10.9,7.7,0.61Hz,2H),6 .43(s,2H),4.49(m,1H),2.33(m,1H),2.17(m,3H),1.32(s,9H);HPLC purity, 99.2%;Chiral purity, 99.9%ee;LCMS(ESI)m / z 348.2,[M+H] + ,292.2[Mt-Bu+H] + . 1 Residual IPA by H NMR: 0.7 mol %.

[0244] Synthesis of 4-(1-(4-bromo-3-fluorobenzyl)azetidin-3-yl)morpholine (compound 4): A mixture of 4-bromo-3-fluorobenzaldehyde (compound 14, 82 g, 396 mmol) and 4-(azetidin-3-yl)-morpholine hydrochloride (compound 7 HCl, 72 g, 396 mmol) in acetonitrile (820 ml) was stirred at 25±5° C. for at least 3 hours. The mixture was cooled to 10±5° C. and sodium triacetoxyborohydride (130 g, 594 mmol) was added in four portions while maintaining the temperature of the mixture below 30° C. The temperature of the mixture was adjusted to 25±5° C. and stirred for at least 30 minutes until the reaction was complete. The mixture was transferred into pre-cooled (10-15°C) aqueous citric acid (152 g, 792 mmol in 400 ml water) while maintaining the temperature below 30°C. Once the quenching process was completed, the mixture was concentrated to approximately 560 ml (7 volumes) while maintaining the temperature below 45°C. The mixture was then washed with toluene (320 ml). THF was added to the aqueous phase and the pH was adjusted to above 12 using aqueous NaOH (320 ml, 10 N). The phases were separated and the aqueous phase was removed. The organic phase was washed with brine and subsequently concentrated by addition of THF (approximately 3 L) until KF ≤ 0.10%. The mixture was filtered to remove any inorganics and the product, compound 4, was isolated as a solution in THF in 95% yield.

[0245] Synthesis of sodium (2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)phenyl)(hydroxy)methanesulfonate (compound 13): A solution of compound 4 (520 g, 1.58 mol) in THF (380 ml) was cooled to -15 ± 5 °C. A solution of iPrMgCl·LiCl (1.3 M, 1823 ml, 2.37 mol) in THF was added over a period of at least 1 h, while maintaining the temperature below -10 °C. Once the addition was complete, the temperature of the reaction mixture was adjusted to 0 ± 5 °C and stirred for at least 1 h. Once the magnesiation was complete, the mixture was cooled to -15 ± 5 °C (target -15 °C to -20 °C) and a solution of DMF (245 mlg, 3.16 mol) in THF (260 ml) was added slowly over a period of at least 1 h, while maintaining the temperature below -10 °C. The temperature of the mixture was then adjusted to -15±5°C and stirred for at least 4 hours.

[0246] Upon completion of the reaction, the reaction mixture was dumped into 3N aqueous HCl (2600 ml) over a period of at least 1 hour while maintaining the temperature below -5°C. The temperature of the mixture was then adjusted to 5±5°C, stirring was stopped, and the mixture was allowed to settle for at least 15 minutes. The layers were separated. The lower aqueous layer containing the product was washed with 2-MeTHF (2600 ml). The aqueous layer was then dumped with 2-MeTHF (2600 ml) and the temperature of the batch was adjusted to -10±5°C. To the cooled mixture was added 5N aqueous NaOH (728 ml, 3.64 mol) while maintaining the temperature below -5°C until the pH of the mixture was between 10-11. The temperature of the mixture was adjusted to 5±5°C and stirred for at least 15 minutes. Stirring of the mixture was stopped and the mixture was allowed to settle for at least 15 minutes. The layers were separated and the lower aqueous layer was back extracted twice with 2-MeTHF (2600 ml). The combined organic layers were washed with water (1040 mL) and the organic solution was evaporated to dryness to give 372 g of crude compound 3 free base as an oil (85% yield). 1H NMR(DMSO-d6)δ(ppm):10.18(s,1H),7.78(t,J=7.7Hz,1H),7.23-7.35(m,2H),3.66 (s,2H),3.51-3.60(m,4H),3.26-3.47(m,2H),2.72-2.97(m,3H),2.12-2.32(m,4H).

[0247] Crude compound 3 free base (4.3 kg) was adsorbed onto silica gel (8.6 kg) with 100% DCM and loaded onto a 60 L column containing 12.9 kg of silica gel (packed with 100% DCM) and eluted with DCM (86 L), followed by successive elution with 1% MeOH / DCM (40 L), 3% MeOH / DCM (80 L) and 10% MeOH / DCM (40 L). Fractions were collected and concentrated below 38° C. to give compound 3 as a refined oil (3.345 kg, 66% yield).

[0248] A portion of compound 3 (1.0 kg, 3.59 mol) was dissolved in ethanol (16.0 L, 16 vol) at 20 ± 5 °C and the mixture was heated to 40 °C. A solution of Na2S2O5 (622.0 g, 3.27 mol; 0.91 eq) in water (2 L, 2 vol) was prepared at 20 ± 5 °C and added to the free base solution at 40 °C to give an off-white suspension. The batch was stirred and held at 40 °C for 2 hours before being cooled to 20 ± 5 °C and stirred for 1-2 hours. The batch was filtered and washed with ethanol (2x2.0 L, 2x2 vol) to give an off-white solid. The wet cake was dried under vacuum at 40 °C for 18 hours to give approximately 1.88 kg of compound 13.

[0249] Synthesis of 2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzaldehyde (compound 3): Compound 13 (1.88 kg) was dissolved in ethyl acetate (15.0 L) at 20±5°C. 2M Na2CO3 solution (total 15.0 L used) was added to adjust the pH to 10.0. The batch was stirred at 20±5°C for 1-1.5 h. Upon completion of the reaction, the phases were separated and the organic layer was washed with brine (2.0 L). The organic layer was concentrated to dryness at 35-38°C to give 852.0 g of compound 3 as a colorless oil (81% yield).

[0250] Synthesis of 2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzaldehyde bisoxalate (bisoxalate of compound 3): A portion of compound 3 oil (187 g, 0.67 mol) was dissolved in isopropanol (1125 ml) and water (375 ml). A first portion (about 30%) (480 ml) of this free base mixture was slowly added to a solution of oxalic acid (125 g, 1.38 mol) in IPA (1125 ml) / water (375 ml) at 60±5° C. over a period of at least 30 minutes. A second portion (about 20%) (320 ml) of the free base mixture was slowly added to the reaction mixture at 60±5° C. over a period of at least 30 minutes. The reaction mixture was stirred at 60±5° C. for at least 90 minutes. A third portion (about 25%) of the free base mixture (about 400 ml) was slowly added to the reaction mixture at 60±5° C. over a period of at least 30 minutes and the reaction mixture was stirred at 60±5° C. for at least 90 minutes. The remaining free base solution (400 ml) was slowly added to the reaction mixture at 60±5° C. over a period of at least 30 minutes and the reaction mixture was stirred at 60±5° C. for at least 90 minutes. The temperature of the mixture was adjusted to 20±5° C. (target 20° C.) over a period of at least 1 hour and the mixture was stirred at 20±5° C. for at least 16 hours before being filtered. The cake was washed three times with IPA (2×375 ml) and dried in a drying oven at ≦40° C. with a slow nitrogen flow to give 261 g of the bis-oxalate salt of compound 3 (85% yield). 1 H NMR(DMSO-d6)δ(ppm):10.21(s,1H),7.87(t,J=7.6Hz,1H),7.42-7.56(m,2H),4.31(s,2H),3.89-4.03(m,2H),3.75-3.89(m,2H),3.60(br t,J=4.3Hz,4H),3.26(br t,J=6.9Hz,1H),2.37(br s,4H).

[0251] Synthesis of tert-butyl (S)-5-amino-4-(4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 2): Acetonitrile (6.8 L, 8.0X Vol) was added to a 30 L jacketed cylindrical reactor. Compound 5 (0.845 kg, 1.00X Wt) and the bis-oxalate salt of compound 3 (1.35 kg, 1.60X Wt) were charged to the reactor followed by additional acetonitrile (5.9 L, 7.0X Vol). The reactor contents were equilibrated to 20±5° C. with stirring. Trifluoroacetic acid (0.19 L, 0.22X Vol) was added dropwise while maintaining the batch temperature at 20±5° C. The reaction mixture was stirred at 20±5°C for not less than 5 minutes and then sodium triacetoxyborohydride (0.13 kg, 015X Wt) was added as a solid while maintaining the batch temperature at 20±5°C. The process of adding trifluoroacetic acid followed by sodium triacetoxyborohydride was repeated five more times. After the final addition, the reaction mixture was sampled to determine the progress of the reaction. The reaction was held at 20±5°C overnight. The reaction mixture was then quenched with water (3.4 L, 4.0X Vol) while maintaining the batch temperature at 20±5°C. The mixture was then stirred at 20±5°C for not less than 30 minutes and the resulting slurry was filtered through a 3 L sintered glass filter and the filtrate poured into a clean container. The reactor was rinsed with acetonitrile (0.4 L, 0.5X Vol), the rinse passed through the contents of the 3 L sintered glass filter, and the filtrate poured into the vessel containing the main batch. The vessel contents were concentrated under reduced pressure to approximately 5X Vol with a batch temperature below 30°C. The residue was transferred to a clean reactor and rinsed with 2-MeTHF (2.5 L, 3.0X Vol) to complete the transfer. Additional 2-MeTHF (10.1 L, 12.0X Vol) was added to the reactor followed by water (3.4 L, 4.0X Vol). The mixture was stirred at 20±5°C for not less than 15 minutes and then allowed to settle at 20±5°C for not less than 10 minutes before transferring the bottom aqueous layer to a new vessel. Aqueous sodium bicarbonate (5.3 L, 6.3X Vol, 9% wt / wt) was added to the reactor with stirring over 30 minutes while maintaining the batch temperature below 25°C.The mixture was stirred at 20±5° C. for no more than 15 minutes and then allowed to settle at 20±5° C. for no less than 10 minutes before the bottom aqueous layer was transferred to a new vessel. The aqueous sodium bicarbonate wash was repeated two more times to achieve a pH of about 6.6 for the spent aqueous layer. A saturated aqueous solution of NaCl (0.85 L, 1.0X Vol) was then added to the reactor with stirring. The mixture was stirred at 20±5° C. for no less than 15 minutes and then allowed to settle for no less than 10 minutes before the bottom aqueous layer was transferred to a new vessel. The remaining organics were concentrated under reduced pressure at a batch temperature of about 40° C. to a batch volume of about 5X Vol. Acetonitrile (5.1 L, 6.0X Vol) was added to the remaining volume and the resulting solution was concentrated under reduced pressure at a batch temperature of about 40° C. to a batch volume of about 5X Vol. The process of adding acetonitrile and concentrating under vacuum was repeated two more times to reach a distillation endpoint of about 1% water content. The acetonitrile solution was transferred to a clean vessel with two 1.7 L (2.0X Vol) rinses and held at 5° C. overnight. The acetonitrile solution was then filtered through a 3 L sintered glass filter followed by a 1.7 L (2.0X Vol) acetonitrile rinse and the filtrate poured into a clean vessel. The filtrate was transferred to a clean reactor and the vessel was rinsed twice with 1.7 L (2.0X Vol) acetonitrile to complete the transfer. Sufficient acetonitrile (approximately 0.6 L) was added to adjust the total volume in the reactor to approximately 14 L. A solution assay of the reactor contents was obtained and the amount of Compound 2 present was calculated for use in the next step (Result=1.3 kg=1.00X Wt for the remainder of the process).

[0252] Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione bisbesylate (bisbesylate of compound 1): The acetonitrile solution of compound 2 from the previous step was diluted with acetonitrile (approximately 2 L) such that the total volume in the reactor was approximately 16 L. The solution was cooled to 10±5° C. with stirring and held within that range for 96 hours. The reaction mixture was sparged with nitrogen gas and benzenesulfonic acid (1.86 kg, 1.43× Wt) was added while maintaining the batch temperature at 10±10° C. The reactor temperature was then adjusted to 20±5° C. and the mixture was stirred at that temperature for 60 minutes. The total volume of the reaction mixture was adjusted back to 16 L to account for solvent loss during sparging by the addition of acetonitrile (approximately 0.4 L). The reaction mixture was then heated to 55±5°C over approximately 30 minutes and held in that range for 15-16 hours for completion of the reaction. The mixture was then cooled to 50±5°C and MTBE (3.9L, 3.0X Vol) was added while maintaining the batch temperature at 50±5°C. The mixture was allowed to stir at 50±5°C for approximately 1.5 hours to establish a self-seeding slurry. Additional MTBE (3.9L, 3.0X Vol) was added to the reactor over approximately 1.75 hours at 50±5°C. The slurry was cooled to 20±5°C over approximately 1.75 hours and held in that temperature range overnight. The slurry was filtered using a Buchner funnel. The reactor was rinsed twice with MTBE (3.9L, 3.0X Vol each) and the rinses were used to wash the solids in the Buchner funnel. The solid was dried under reduced pressure (15-150 mbar) at 40° C. on a drying tray for approximately 23 hours to give 1.62 kg (77.9%) of the bisbesylate salt of compound 1.

[0253] Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione hydrochloride (compound 1 HCl): A suspension of the bisbesylate salt of compound 1 (120 g, 1 equiv.) in 2-MeTHF (25 L / kg) was added to a reactor and stirred at 10° C. A solution of KHCO3 (32.5 g, 2.4 equiv.) in water (1.8 L, 6 L / kg) was added to the slurry over 40 min. The mixture was stirred for an additional 30 min. The batch was then allowed to settle at which point the aqueous (bottom) layer was separated and discarded. An aqueous solution of NaCl (5%, 5 L / kg, 575 ml) was added to the organic layer and the mixture was stirred for 10 min, after which the temperature was increased to 20° C. The batch was allowed to settle at which point the aqueous (bottom) layer was discarded. The brine was repeated once more. Additional 2-MeTHF (500 ml) was added to dilute the organic layer to give a concentration of about 20 mg of product per ml. A solution of HCl (0.98 eq. total) in 2-MeTHF was prepared and then a portion of it (20% of the total, equivalent to about 0.2 eq.) was added to the reaction mixture over about 10 minutes. A seed of the hydrochloride salt of compound 1 (about 5% wt.) was added but did not dissolve. The batch was held under vigorous stirring for 1 hour. To the slurry was added the remaining portion of the HCl solution (about 0.78 eq.) at a constant rate over 3 hours. Vigorous stirring was maintained. Once addition was complete the batch was held for 1 hour after which it was filtered and washed 3 times with 3 L / kg of 2-MeTHF. The filter cake was placed in a vacuum oven at 22° C. for 12 hours at which point the temperature was increased to 40° C. A dry cake of the hydrochloride salt of compound 1 (58 g, 75% yield) was obtained and packaged. Achiral HPLC purity: 98.91%; Chiral HPLC purity: 99.68%.

[0254] Example 3: Additional Information for the Preparation of Compound 1 Hydrochloride from Compound 1 Bisbesylate The free base of compound 1 is sensitive to aqueous base and racemization was observed. The rate is time and temperature sensitive (Table 1). Isolation of the crystalline bis-besylate salt of compound 1 avoids the need for pH variation. The crystalline free base is also in a poor form which slows filtration and increases the risk of racemization. Racemization was also observed during filtration. The chiral purity data in Table 2 highlight the advantage of isolating the more stable bis-besylate salt compared to the crystalline free base.

[0255] [Table 1]

[0256] [Table 2]

[0257] No improvement was observed in terms of both achiral and chiral purity from crystallization of the hydrochloride salt of Compound 1 from the isolated free base of Compound 1. Isolation of the free base resulted in less crystalline material, which slowed filtration and ultimately reduced chiral purity over time. The isolated free base had an HPLC purity of 95.8% and a chiral purity of 97.5% (Table 2). On the other hand, the method of Example 2, which involves freebasing the bisbesylate salt followed by crystallization from the hydrochloride salt solution, provided significant improvement (Table 3). Without being limited by any particular theory, it is the biphasic nature of this salt decomposition that is important for the improvement in purity.

[0258] [Table 3]

[0259] Example 4: Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione [ka] Synthesis of tert-butyl (S)-5-amino-4-(4-nitro-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 6): To a solution of 3-nitrophthalic anhydride (compound 12, 35.15 g, 176.6 mmol, 1.00 eq) in ethyl acetate (350 mL) was added tert-butyl (4S)-4,5-diamino-5-oxo-pentanoate hydrochloride (compound 9 HCl, 43.22 g, 181.1 mmol, 1.025 eq), DMF (70 mL) and 2-MeTHF (110 mL) at 25 °C. 2,6-lutidine (23.4 mL, 201 mmol, 1.14 eq) was added slowly to maintain the temperature below 25 °C. The mixture was aged at 25 °C for 1 h and then cooled to 5 °C. CDI (4.17 g, 25.7 mmol, 0.146 eq) was added and stirred until the temperature returned to 5° C. Another portion of CDI (4.62 g, 28.5 mmol, 0.161 eq) was added and stirred until the temperature returned to 5° C. CDI (8.87 g, 54.7 mmol, 0.310 eq) was added and stirred until the temperature returned to 5° C. CDI (8.91 g, 54.9 mmol, 0.311 eq) was added and stirred until the temperature returned to 5° C. The mixture was warmed to 20° C., CDI (16.4 g, 101.1 mmol, 0.573 eq) was added and the mixture was aged at 20° C. for 16 hours. The mixture was cooled to 5° C. and a solution of 30 wt % citric acid and 5 wt % NaCl (350 mL) was added slowly while maintaining the temperature. The mixture was warmed to 20° C. and aged for 30 minutes. The phases were partitioned and separated. The organic phase was diluted with EtOAc (175 mL), diluted with a solution of 5 wt% citric acid (175 mL) and concentrated by distillation (75 torr, 50° C.) to a volume of 175 mL EtOAc. The solvent was changed to iPrOH by constant volume distillation (75 torr, 50° C.) with 350 mL iPrOH to a final volume of 175 mL. The distillate was diluted with 200 mL iPrOH to give compound 6 as a solution for use in the next step. 1H NMR(500MHz,CDCl3)δ(ppm):8.18-8.13(m,2H),7.96(t,J=7.8Hz,1H),6.34(s,1H),5.59(s,1H),4.90(dd,J=10.1,4 .6Hz,1H),2.61(ddt,J=14.6,10.1,6.1Hz,1H),2.49(ddt,J=14.2,8.7,5.2Hz,1H),2.44-2.29(m,2H),1.44(s,9H).

[0260] Synthesis of tert-butyl (S)-5-amino-4-(4-amino-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 5): To a solution of compound 6 in iPrOH (375 mL) was added 5% palladium on carbon (1.23 g, 3.5 wt%, wet). The mixture was purged with nitrogen five times and with hydrogen three times. The mixture was pressurized with hydrogen (50 psi) and aged at 50° C. for 16 h. The mixture was cooled to room temperature, purged with nitrogen three times, filtered to remove the catalyst, and the filter cake was washed three times with iPrOH (20 mL). The filtrate was concentrated to 200 mL, seeded (0.454 g, 1.3 wt%) at 22° C., and aged for 45 min. Water (1325 mL) was added over 3 h at 22° C. After the addition of water, the mixture was cooled to 8 °C over 2 h and aged at 8 °C for 1 h. The slurry was filtered and the cake was rinsed three times with cold water (200 mL) and dried under vacuum at 50 °C to give compound 5 as a yellow solid (47.97 g, 80.6% yield, 99.62% LC purity, 1 H NMR efficacy 103%). 1 H NMR(500MHz,CDCl3)δ(ppm):7.46(dd,J=8.3,7.0Hz,1H),7.19(d,J=7.2Hz,1H),6.89(d,J=8.3Hz,1H),6.28(s,1 H),5.41(s,1H),5.28(s,2H),4.83(dd,J=9.3,6.0Hz,1H),2.52(p,J=7.0Hz,2H),2.36-2.29(m,2H),1.44(s,9H). 13C NMR(126MHz,CDCl3)δ(ppm):171.80,171.12,169.64,168.27,145.70,135.50,132.20,121.43,112.98,80.99,53.04,32.23,28.02,24.36.LCMS(ESI):m / z 291.9[M+H-tBu]

[0261] Synthesis of 4-(1-(4-bromo-3-fluorobenzyl)azetidin-3-yl)morpholine bismethanesulfonate (bismethanesulfonate salt of compound 4): A mixture of 4-bromo-3-fluorobenzaldehyde (compound 14, 102 g, 493 mmol) and 4-(azetidin-3-yl)morpholine hydrochloride (compound 7 HCl, 90 g, 493 mmol) in acetonitrile (1000 ml) was stirred for 2-3 hours at a temperature of about 20-25° C. The slurry was cooled to a temperature of about 10-15° C. and sodium triacetoxyborohydride (STAB, 162 g, 739 mmol) was added in four portions over a period of about 45 minutes while maintaining the batch temperature below 30° C. The slurry was stirred at a temperature of about 20-25°C for at least 30 minutes and then quenched with aqueous citric acid (191 g, 986 mmol in 500 ml water) at a temperature of about 40-45°C for 2 hours. Upon completion of the quenching process, the batch volume was reduced to about 700 ml by vacuum distillation at a temperature of 45°C or less. Cyclopentyl methyl ether (CPME, 400 ml) was added to the aqueous solution to obtain a final volume of about 1100 ml. The pH was adjusted to about 8-9 by the addition of 10N aqueous NaOH (volume added was about 430 ml). The phases were separated and the aqueous phase was discarded. The organic phase was washed twice with brine (100 ml) to a pH of 8 or less and the volume was adjusted to about 1000 ml by the addition of extra CPME. The batch was distilled at constant volume under reduced pressure by the addition of CPME until the KF was 0.15% or less. CPME was added (if necessary) to adjust the batch to a volume of 1000 ml at the end of the distillation. Dry CPME solution was seeded (500-750 mg) at ambient temperature. The seeded dry CPME slurry was heated to a temperature of 50-60° C. before charging with 200 ml of methanesulfonic acid in CPME over 4-5 hours. The slurry was then cooled to 20° C. over 4-5 hours, held at 20° C. for 3-4 hours, filtered, rinsed with CPME, and dried in a vacuum oven at 35-40° C. for 16 hours to give the bismethanesulfonate salt of compound 4 as a white solid. 1H NMR(500MHz DMSO-d6)δ(ppm):10.62(br s,1-2H),7.85(t,J=7.8Hz,1H),7.58(dd,J=9.5Hz,1.9Hz,1H),7.34(dd,J=8.2Hz,1.8Hz,1H),4.55-4.24(m,7H),3.84(br s,4H),3.14(m,4H);HPLC purity,99.8%,LCMS(ESI)m / z 329.1 / 331.1[M / M+2] + The XRPD pattern of the product is shown in Figure 10. The DSC thermogram of the product is shown in Figure 11.

[0262] Preparation of 4-(1-(4-bromo-3-fluorobenzyl)azetidin-3-yl)morpholine (compound 4): A slurry of compound 4 bismethanesulfonate (70 g, 134 mmol) in t-butyl methyl ether was cooled to 10±5° C. An aqueous solution of NaOH (2N, 201 ml, 403 mmol) was added over at least 30 minutes while maintaining the batch temperature at about 15° C. After the addition of NaOH, the batch temperature was raised to 20±5° C. and stirred for about 20 minutes. The organic layer was separated and washed three times with water (210 ml). The organic layer was then concentrated by the addition of THF (about 1.05 L) until KF≦0.10%. The product compound 4 was isolated as a THF solution in 95% solution yield.

[0263] Preparation of 2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzaldehyde dihydrochloride (compound 3 di-HCl): Next, a solution of compound 4 (44 g, 134 mmol) in THF (total volume approximately 350 ml) was cooled to -20 ± 5 °C. A solution of iPrMgCl·LiCl (1.3 M, 176 ml, 228 mmol) in THF was added over 30 minutes while maintaining the temperature below -10 °C. Once the addition was complete, the batch was stirred at -20 ± 5 °C for 16-22 hours. Next, DMF (21 ml, 268 mmol) was added slowly over 30 minutes while maintaining the batch temperature below -15 °C. The batch was stirred at -20 ± 5 °C for 6-24 hours. 2-MeTHF (350 ml) was then added to the batch over 30 minutes, followed by the slow addition of 3N HCl (235 ml, 704 mmol) while maintaining the batch temperature at or below -10°C. After the addition of aqueous HCl, the batch was warmed to 0±5°C and 2N aqueous NaOH (154 ml, 309 mmol) was slowly added to adjust the pH of the solution to about 8-9. The batch was stirred for about 30 minutes and then warmed to 20±5°C. The organic layer was separated and washed with 15% aqueous NaCl (3x140 ml). The organic layer was then concentrated by the addition of 2-MeTHF until KF≦0.10%.

[0264] A portion of the so obtained free base of 2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzaldehyde (37.4 g, 134 mmol) was dissolved in 2-MeTHF (approximately 420 ml total) to which was added isopropanol (420 ml) and water (21 ml) at 20±5° C. The batch was then heated to 50±5° C. and HCl in IPA (5-6N, 28 ml, half of the total HCl volume) was added over 1 hour. The batch was seeded with 2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzaldehyde dihydrochloride (700 mg) and aged for 1 hour. The remaining HCl (28 ml) was then added over 1 hour. The batch was stirred at 50±5° C. for 4 hours and then cooled to 20±5° C. for 8 hours. The slurry was filtered, washed with IPA (210 ml) and the filter cake was dried under vacuum at 50±5° C. to give the dihydrochloride salt of compound 3 (36 g, 75% yield). 1 H NMR (DMSO-d6) δ (ppm): 12.32-12.55 (m, 1H), 10.23 (s, 1H), 7.93 (t, J = 7.6 Hz, 1H), 7.66 (d, J = 10.5 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 4.80 (br s, 2H), 4.48-4.70 (m, 2H), 4.30 (br s, 4H), 3.78-4.00 (m, 5H), 2.93-3.15 (m, 2H). Two polymorphic forms were obtained. The XRPD pattern and DSC thermogram of Form A (anhydrous) are shown in Figures 5 and 6, respectively. The XRPD pattern, TGA thermogram and DSC thermogram of Form B (hydrate) are shown in Figures 7, 8 and 9, respectively.

[0265] Synthesis of tert-butyl (S)-5-amino-4-(4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)-1,3-dioxoisoindolin-2-yl)-5-oxopentanoate (compound 2): A mixture of compound 5 (12 g, 34.5 mmol, 1.0 eq) and the dihydrochloride salt of compound 3 (14.56 g, 41.5 mmol, 1.2 eq) in MeCN (96 ml) was cooled to 0-5 °C. While maintaining the internal temperature below 10 °C, trifluoroacetic acid (TFA, 2.0 ml, 26 mmol, 0.75 eq) was added followed by sodium triacetoxyborohydride (STAB, 2.75 g, 12.95 mmol, 0.375 eq). The addition of TFA and STAB was repeated three more times. After a total of four additions of TFA and STAB, the reaction was aged at 0-5°C for 1 hour. Then, 10% aqueous brine (108 ml) was added to the reaction mixture over 1 hour and partitioned with IPAc (96 ml). The mixture was warmed to 20-25°C and aged for 30 minutes. The layers were then separated and the organic layer was washed with 2.0 M K3PO4 (114 ml). The pH of the spent aqueous layer should have a pH of approximately 8.5-9.0. The layers were again separated and the organic phase was washed with 8.5% NaHCO3 (2x60 ml) followed by 24% brine (60 ml), with 30 minutes between each wash. The organic fraction was distilled to 72 ml at an internal temperature of around 50°C. Toluene (72 ml) was added to bring the volume to 144 ml and distillation was continued at constant volume by feed and bleed at 50°C until the water content was less than 0.1. The mixture was heated to 50°C and acetonitrile (48ml) was added followed by slow addition of heptane (144ml) while maintaining the internal temperature above 45°C. The reaction was held at 50°C for 2 hours. Upon completion, the reaction was slowly cooled to 20-25°C over 4 hours and held at 20-25°C overnight (16 hours). The yellow slurry was then filtered and the yellow cake was displacement washed with a 1:3:3 mixture of acetonitrile / heptane / toluene (3x48ml). The final cake was then dried under reduced pressure under nitrogen at 50°C to provide compound 2 (87.7% isolated molar yield) with an LCAP of >99.0%. HPLC purity, 99.85%; chiral purity, >99.9%ee.1 H NMR(DMSO-d6,500MHz)δ(ppm)7.55(s,1H),7.51(dd,J=7.2,8.4Hz,1H),7.32(t,J=7.9Hz,1H),7.16(s,1H),7.0-7.1(m,5H),4.57(d, LCMS m / z 610.3[M+H] + .

[0266] Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione bisbesylate (bisbesylate salt of compound 1): To a stirred suspension of compound 2 (130 g, 1.0 equiv.) in MeCN (1.56 L, 12 L / kg) at 55° C. was added a solution of benzenesulfonic acid (185 g, 5.5 equiv.) in MeCN (0.39 L, 3 L / kg) and water (0.01 L, 2.0 equiv.). The mixture was stirred at 55° C. for 16 h. After aging of the reaction, crystalline seeds of the bisbesylate salt of compound 1 (1.3 g, 1 wt %) were charged in batches resulting in the formation of a yellow slurry. The slurry was then cooled to 20° C. over 90 min. 2-MeTHF (1.3 L, 10 L / kg) was added slowly to the batch over 2 hours at 20° C. The batch was stirred for an additional 4 hours at 20° C. The yellow slurry was then filtered and the yellow cake was reslurried with MeTHF (1.3 L, 10 L / kg) followed by a displaced MeTHF (0.65 L, 5 L / kg) wash. The final cake was then dried under reduced pressure at 50° C. under nitrogen to give the bis-besylate salt of compound 1 (160 g, 88.4% yield). HPLC purity: 98.39%; Chiral HPLC purity: 100%. The XRPD pattern, TGA thermogram and DSC thermogram of the product are shown in FIG. 1, FIG. 2 and FIG. 3, respectively.

[0267] Synthesis of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione hydrochloride (compound 1 HCl): A suspension of the bisbesylate salt of compound 1 (300 g, 1 equiv.) in EtOAc (4.68 L, 15.6 L / kg) and 2-propanol (0.12 L, 0.4 L / kg) was stirred at 15° C. To this suspension was added a solution of KHCO3 (82.4 g, 2.5 equiv.) in water (1.8 L, 6 L / kg) over 30 min. The mixture was heated to 20° C. over 30-60 min and then stirred for 30 min. The batch was allowed to settle for 30 min at which point the aqueous (bottom) layer was discarded. Water (1.2 L, 4 L / kg) was added to the rich organic layer and the reactor contents were stirred for 30 minutes. The batch was allowed to settle for 30 minutes at which point the aqueous (bottom) layer was discarded. 2-propanol (2.375 L, 7.9 L / kg) was added to the rich organic stream and the stream was then filtered. Water was added to the filtrate to adjust the water content to 8≦KF≦8.2. 0.2 N HCl (38 mL, 0.025 equiv., prepared in EtOAC / IPA 2:1, v / v with 8 wt% water) was added to the above stirred solution at 20° C. over 10 minutes. Crystalline seeds of the hydrochloride salt of compound 1 (1.6 g, 0.5 wt%) were added to this mixture and the reactor contents were stirred for 30 minutes at 20° C. To this suspension was added 0.2N HCl (1.44 L, 0.945 eq., prepared in EtOAC / IPA 2:1, v / v, containing 8 wt% water) over 4.5 h. The slurry was stirred for 14 h, then filtered and washed with EtOAC / IPA (750 mL, 2.5 L / kg, 2:1 v / v, containing 8 wt% water), followed by IPA (750 mL, 2.5 L / kg). The solid was dried under vacuum at 40° C. to give the hydrochloride salt of compound 1 (170 g, 90% yield). Achiral HPLC purity: 99.91%; Chiral HPLC purity: 99.58%. XRPD analysis (FIG. 4) confirmed that the product (a) was Form A of the hydrochloride salt of compound 1 by comparison with a reference sample (b).

[0268] The above embodiments are intended to be merely illustrative, and those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific compounds, materials and procedures, all of which are considered to be within the scope of the claimed subject matter and are encompassed by the claims.

[0269] All patents, patent applications, and publications referenced herein are hereby incorporated by reference in their entirety. Citation or identification of any reference in this application is not an admission that such reference is available as prior art to the claimed subject matter.

Claims

1. Formula (I): 【Chemical 1】 A method for preparing a compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, comprising: (Step 1.0) A compound of formula (II): 【Chemical 2】 is cyclized to provide a compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof; and (Step 1.1) Optionally, converting the compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, to a salt of the compound. A method comprising.

2. The method according to claim 1, wherein step 1.0 is carried out in the presence of an acid.

3. The method according to claim 2, wherein the acid is benzenesulfonic acid.

4. The method according to claim 3, wherein the compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, prepared in step 1.0 is a besylate.

5. The method according to claim 1 or 2, wherein step 1.0 is carried out in a solvent of acetonitrile, methyltetrahydrofuran, water or a combination thereof.

6. The method according to claim 1 or 2, wherein in step 1.1, the compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is converted to a hydrochloride salt of the compound.

7. The method according to claim 6, wherein in step 1.1, the salt of the compound of formula (I) is contacted with a basic aqueous solution and subsequently acidified.

8. The method according to claim 7, wherein the basic aqueous solution is a bicarbonate solution.

9. The method according to claim 7, wherein the acidification comprises the addition of hydrochloric acid.

10. The method according to claim 6, wherein step 1.1 is carried out in a two-phase mixture comprising an aqueous solution and an organic solvent.

11. The method according to claim 6, wherein step 1.1 is carried out in a solvent of ethyl acetate (EtOAc), isopropanol (IPA) or water.

12. The compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, (Step 2.a) a compound of formula (II-A): 【Chemical Formula 3】 or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof is reacted with 4-(azetidin-3-yl)morpholine or a salt thereof, optionally in the presence of a base. The method according to claim 1 or 2, which is prepared by a method comprising the step.

13. The compound of formula (II-A), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, (Step 2.b) a compound of formula (II-B): 【Chemical Formula 4】 or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof is chlorinated, optionally in the presence of methanesulfonyl chloride (MsCl) and / or a base. The method according to claim 12, which is prepared by a method comprising the step.

14. The compound of the formula (II-B), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, (Step 2.c) Formula (V): [Chemical Formula 5] reacting the compound of the formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, with 2-fluoro-4-(hydroxymethyl)benzaldehyde, optionally in the presence of a reducing agent and / or an acid The method according to claim 13, which is prepared by a method comprising

15. The compound of the formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, (Step 2.0) Formula (III): [Chemical Formula 6] reacting the compound of the formula (III), or a salt, solvate, hydrate or isotopologue thereof, optionally a bis hydrochloride or bis oxalate, with the compound of the formula (V): [Chemical Formula 7] or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, optionally in the presence of a reducing agent and / or an acid The method according to claim 1 or 2, which is prepared by a method comprising

16. The compound of the formula (III), or a salt, solvate, hydrate or isotopologue thereof, (Step 3.0) Formula (IV): [Chemical Formula 8] prepared by a method comprising reacting the compound of the formula (IV), or a salt, solvate, hydrate or isotopologue thereof, with a formaldehyde source, optionally in the presence of an organomagnesium reagent, and optionally in Step 3.0, the compound of the formula (III), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is converted to the bis hydrochloride of the compound, the method according to claim 15

17. (Step 3.a) Reacting the compound of formula (III) prepared in Step 3.0, or a salt, solvate, hydrate or isotopologue thereof, with Na ２ S ２ O ５ to provide a sodium sulfonate compound of the formula: 【Chemical Formula 9】 or a salt, solvate, hydrate or isotopologue thereof; and (Step 3.b) Converting the sodium sulfonate compound to the compound of formula (III), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, wherein, optionally in Step 3.b, the compound of formula (III), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is converted to the bisoxalate salt of the compound, according to the method of claim 16.

18. The compound of formula (IV), or a salt, solvate, hydrate or isotopologue thereof, is (Step 4.0) Reacting 4-(azetidin-3-yl)morpholine or a salt thereof, optionally the hydrochloride salt of 4-(azetidin-3-yl)morpholine, with 4-bromo-3-fluorobenzaldehyde, optionally in the presence of a reducing agent. prepared by a method comprising, wherein, optionally in Step 4.0, the compound of formula (IV), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is converted to the methanesulfonate salt of the compound, according to the method of claim 16.

19. The compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is (Step 5.0) Of formula (VI): 【Chemical Formula 10】 The step of reducing the compound of , or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof A process according to claim 15, prepared by a process comprising, optionally, step 5.0 being carried out by hydrogenation and / or in the presence of a catalyst.

20. The compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is (Step 6.0) a step of reacting (S)-tert-butyl 4,5-diamino-5-oxopentanoate of the formula: 【Chemical Formula 11】 or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof with 3-nitrophthalic anhydride in the presence of a base and / or an activating reagent A process according to claim 19, prepared by a process comprising.

21. The compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, is (Step 6.a) a step of reacting (S)-tert-butyl 4,5-diamino-5-oxopentanoate of the formula: 【Chemical Formula 12】 or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof with ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate of the formula: 【Chemical Formula 13】 in the presence of a base, if appropriate. A process according to claim 19, prepared by a process comprising.

22. Ethyl 4-nitro-1,3-dioxoisoindoline-2-carboxylate is (Step 6.b) a step of reacting 4-nitroisoindoline-1,3-dione with ethyl chloroformate in the presence of a base, if appropriate. The method according to claim 21, prepared by a method comprising **Claim 23** A compound of formula I, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, (Step 1.0) cyclizing a compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, to provide a compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof; (Step 1.1) optionally, converting the compound of formula (I), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, to a salt of said compound prepared by a method comprising, wherein the compound of formula (II), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, (Step 2.0) reacting a compound of formula (III), or a salt, solvate, hydrate or isotopologue thereof, with a compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof prepared by a method comprising, wherein the compound of formula (III), or a salt, solvate, hydrate or isotopologue thereof, (Step 3.0) reacting a compound of formula (IV), or a salt, solvate, hydrate or isotopologue thereof, with a source of formaldehyde prepared by a method comprising, wherein the compound of formula (IV), or a salt, solvate, hydrate or isotopologue thereof, (Step 4.0) reacting 4-(azetidin-3-yl)morpholine or a salt thereof with 4-bromo-3-fluorobenzaldehyde prepared by a method comprising, wherein the compound of formula (V), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof, (Step 5.0) Reducing the compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof Prepared by a method comprising, wherein the compound of formula (VI), or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof is (Step 6.0) Reacting (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof with 3-nitrophthalic anhydride The method according to claim 1, prepared by a method comprising.

24. The besylate salt of Compound 1; A compound which is Compound 2, Compound 2-a, Compound 2-b, Compound 3, Compound 4, Compound 5 or Compound 6, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers or isotopologue thereof; Compound 1: 【Chemical Formula 14】 A solid form comprising the besylate salt of, optionally in Form B of the besylate salt of Compound 1, characterized by an XRPD pattern comprising peaks at about 6.7, 7.5 and 17.2° 2θ; Compound 3: 【Chemical Formula 15】 A solid form comprising the hydrochloride salt of, optionally in Form A of the hydrochloride salt of Compound 3, characterized by an XRPD pattern comprising peaks at about 14.6, 19.4 and 21.8° 2θ, or in Form B of the hydrochloride salt of Compound 3, characterized by an XRPD pattern comprising peaks at about 14.3, 15.4 and 16.2° 2θ; or Compound 4: 【Chemical Formula 16】 A solid form comprising a methanesulfonate of , optionally in Form A of the methanesulfonate of Compound 4, characterized by an XRPD pattern comprising peaks at about 18.6, 20.3 and 20.8° 2θ.

Images